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ABSTRACT 
Design of Potential Antiprotozoa1 Daunorubicin Derivatives 
by: Mark Alan Hardman 
Daunorubicin is an antitumour antibiotic which is highly active 
against the sleeping sickness parasite Trypanosoma rhodesiense 
in vitro, but which lacks in vivo activity. The object of this 
work was to modify daunorubicin so as to promote in vivo activity, 
and to study the mechanism by which daunorubicin is trypanocidal. 
A series of daunorubicin analogues, and derivatives in which 
daunorubicin was linked to a macromolecular carrier (known as 
daunorubicin conjugates) were prepared, and tested against 
trypanosome infected mice. Only daunorubicin conjugates in which 
drug was linked to the carrier by glutaraldehyde, were active. 
Treatment with these conjugates increased the survival time of 
infected mice from three days to as long as eleven days, and 
temporarily cleared parasites from the bloodstream of infected 
animals. Conjugates with other types of linkage were inactive. 
A fluorescence assay method was developed to measure drug release 
from conjugates. Investigation revealed that glutaraldehyde 
linked conjugate released about 20% of bound drug over a 2-3 hour 
period when incubated in murine plasma. In contrast, inactive 
conjugates either released bound drug very rapidly, or were stable 
to drug release. 
Daunorubicin is known to possess several potentially cytotoxic 
mechanisms of action, the most important being intercalation into 
the DNA double hel~x and stimulation of superoxide radical formation. 
In order to discover the contribution of these mechanisms to 
trypanocidal activity, the trypanocidal potency of a series of 
daunorubicin analogues was assessed in vitro. The ability of these 
analogues to intercalate into DNA and to stimulate lipid peroxidation 
and oxygen consumption was also assessed. The results were used to 
explore the relationship between these mechanisms and trypanocidal 
activity. These studies indicate that ability to bind to DNA is 
important in conferring trypanocidal activity on this group of 
antibiotics. 
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CHAPTER 1 : INTRODUCTION 
1.1 Parasitism as a major world health problem 
Parasitic diseases are considered to be a major obstacle to social 
and economic progress throughout the Third World (Schultz, 1976), 
although they are no longer regarded as a major health problem among the 
developed nations. Parasitic diseases are very prevalent (Table 1), 
especially in tropical regions (Duke, 1978). The importance of parasitic 
diseases has been recognised by the World Health Organisation, and of 
the six diseases which it has selected for consideration in the Special 
Programme for Research and Training in Tropical Diseases, five are 
parasitic diseases (de Maar, 1979); (the sixth, leprosy, is a bacterial 
disease). 
Table 1.1: Prevalence of human parasitic diseases 
Disease Number infected (10-
6) Reference 
Ascariasis 1269 Peters 1978 
Ancylostomiasis 932 Peters 1978 
Schistosomiasis 271 Peters 1978 
Onchocerciasis 20-40 Duke 1981 
Filariasis 657 Peters 1978 
Malaria 100 Brown ':t al 1976 
Trypanosomiasis 13-14 Zeledon 1981 
(Chagas disease) 
Trypanosomiasis 0.01 Foulkes 1981 
(sleeping sickness) 
Leishmaniasis 0.4 World Health 
Organization 1979 
Amoebiasis 400 Haworth 1975 
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Most parasites cause chronic diseases which, although rarely fatal, 
increase the infected individual's susceptibility to intercurrent 
infection and decrease his capacity for work (Peters, 1978). As well as 
suffering from their intrinsic effects, man is excluded from areas where 
transmission of pathogenic parasites is a high risk, and he is therefore 
unable to fully exploit the natural resources of the region. In areas 
of Africa worst affected by onchocerciasis(river blindness), where up 
to 15% of the inhabitants may be blind, the communities cease to be 
economically viable and the inhabitants are forced to desert the fertile, 
but infested, valleys (Duke, 1981). 
The complicated life cycles of parasites provide many opportunities 
for controlling the diseases they cause. The use of chemicals to destroy 
the invertebrate intermediaries has assumed major importance in the 
last thirty years. However, environmental hazards 
associated with the use of chemicals have prompted the adoption of 
alternative, ecological methods of control, such as preventi~n of 
man-parasite contact and destruction of potential breeding places. 
(Rajagopalan and Shiffman, 1974). Whilst these methods are important, 
chemotherapeutic agents are essential for the maintenance of health, 
prevention of the spread of disease where infection by the parasite 
. cannot be prevented, and by attacking the parasite, where it already 
exists in the body. High development costs and the 
uncertainty of an adequate return on investment have limited the 
introduction of new drugs for parasitic diseases, hence the search for 
new drugs needs to be intensified (de Maar, 1979). 
Trypanosomiasis is a particularly important protozoal parasitic 
disease found in much of South America and tropical Africa. African 
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trypanosomiasis of domestic stock (~agana) is highly pathogenic to 
cattle, preventing the exploitation of much of the African savannah 
for cattle rearing (Wilson et al., 1963). 
According to Duggan (1973), the human disease (sleeping sickness) 
if untreated "has the highest case fatality of any cormnunicable disease 
except that of rabies". There have been no new drugs introduced for 
treatment of either the human or animal disease during the last twenty-
five years, and many of the existing drugs are structurally related, 
hence cross resistance can sometimes occur (Williamson, 1976). There 
is an urgent need for fundamental research to develop new trypanocidal 
drugs which do not bear a close structural relationship to existing 
drugs in their mechanism of action (World Health Organisation, 1979). 
1.2 Trypanosomiasis 
Trypanosomes are parasitic protozoa of the genus Trypanosoma 
(order k1netoplastida) and are found in the blood and tissues of many 
animals throughout the world (Hoare 1970)'. Although most of the genus 
Trypanosoma do not produce disease in their hosts, some species cause 
serious disease in man and domestic animals. The genus Trypanosoma 
is sub-divided into the Stercoraria and the Salivaria (Hoare, 1964), 
these being distinguished by the manner (faecal or salivary), in which 
the parasites are transmitted by the arthropod vector. The most 
important stercorarian trypanosome is Trypanosoma (Sahisotrypanum) 
arusi, the causative organism of Chagas'disease in South and CentraJ 
AmerL~a (Ormerod, 1979). This parasite differs significantly from 
the salivarian trypanosomes in life cycle (Hoare, 1970), insect vectors 
(Zelp.doT" and ~a1:>inovich, 1981), and metabolism (Fairlamb, 1982; 
Gutteridge, 1981). 
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The salivarian trypanosomes cause the animal disease na~ana in 
cattle and horses (Trypanosoma (Trypanozoon) brucei brucei, Trypanosoma 
(Nannomonas) congoZense and Trypanosoma (DuttoneZZa) Vivax, surra 1n 
horses and camels (Trypanosoma (Trypanozoon) evansi)and the human 
disease sleeping sickness (Trypanosoma (Trypanozoon) brucei gambiense 
and Trypanosoma (Trypanozoon) brucei rhodesiense)· 
1.2.1 African Human Trypanosomiasis (Sleeping Sickness) 
Sleeping sickness was first described in 1742 by John Atkins, a 
naval surgeon, but the cause was not established until 1902, when 
R.M. Forde and J.E. Dutton found trypanosoma in the blood of a steamboat 
captain on the River Gambia (Dutton, 1902). The parasite, which is 
morphologically identical to the animal trypanosome T. brucei(Bruce, 
1895) was subsequently named Trypanosoma brucei gambiense. Following 
a massive outbreak of sleeping sickness in the Lake Victoria region, 
a commission, consisting of David Bruce, Count Aldo Castellani and 
David Nabarro was appointed by the Royal Society to investigate the 
disease, and by 1903 they had obtained evidence that the tsetse fly 
was the vector for sleeping sickness (Castellani, 1903). The disease 
had long been established in its primordial foci in the river basins 
of West Africa, where it was a chronic disease, well adapted to the 
local population (Duggan, 1970). By the end of the nineteenth century, 
European colonial powers had established regular traffic with inland 
areas of Africa, leading to the introduction of sleeping sickness into 
areas Where it had previously been unknown. The disease flourished, 
and by 1906 half a million people in the Congo basin had died from the 
disease. 
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Owing to control and surveillance measures, sleeping sickness is 
now in a "state of controlled epidemicity" (de Raadt, 1976) with about 
10,000 cases reported to the World Health Organisation each year 
(Foulkes, 1981). However, where surveillance is not maintained, the 
disease is quick to re-establish itself. This was demonstrated in Zaire 
between 1960 and 1961, during a period of civil war. The prevalance, 
which had been kept under 0.02% for several years, rose to epidemic 
proportions before systematic surveillance was restored (Scott, 1970). 
Gambian sleeping sickness is found in the rain forest and moist 
savannah regions of tropical West Africa from the Sahara to the 
Namibian Desert (Ady, 1965). The disease is transmitted by 'riverine' 
tsetse flies of the Glossina palpalis group. Contact with man occurs 
at such sites as river crossing points and water holes where man and 
tsetse fly come in close contact (Scott, 1970). Man is the most 
important host for Trypanosoma bruaei gambiense, and the disease is 
normally spread by a man-tsetse fly-man cycle (Scott, 1970). However 
Gibson et a1 (lJ7B) de~onstrated coat pigs and dogs can also harbour the 
parasite enabling the disease to survive in uninhabited regions 
(Mehlitz et al., 1981). 
By 1910 it became apparent that there are two kinds of sleeping 
sickness when Stephens and Fantham (1910) isolated a virulent strain 
of trypanosoma from a patient in Zambia. This trypanosoma was subsequently 
named Trypanosoma bruaei phodesiense. It is transmitted by flies of 
the Glossina mopsitans group which inhabit the savannah plains of 
East Africa. Wild animals, especially bushbuck, are the usual hosts 
(Ashcroft, 1959), and man is at risk only when he encroaches upon tsetse 
areas either for farming or for hunting. 
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1.2.2 Clinical features of Sleeping Sickness 
The onset and early stages of both Gambian and Rhodesian forms of 
the disease are similar. The first sign may be the development of a 
lesion around the site of the tsetse fly bite usually about 8-10 days 
after infection. This trypanosomal chancre is commonly seen in white, 
but rarely in black, patients (Apted, 1980). A high fever, starting 
about ten days after the original bite, and accompanied by headache 
and sometimes rigours and vomiting, is usual in both the Gambian and 
the Rhodesian diseases (Apted, 1980). Debility, changes in personality 
and bouts of fever are also characteristic; this phase of the disease 
may last for months in the Gambian form, but in the Rhodesian form it 
is much shorter. In the final stage of the disease, the parasites 
invade the central nervous system and may be detected in the cerebro-
spinal fluid (Apted, 1970). This final stage is characterised by 
nervous tremors, fits and the daytime somnolence which gives the disease 
its name. In the final weeks, somnolence deepens into coma, and 
death soon follows, although often from a concurrent infection such 
as pneumonia. The natural duration of , 
the Gambian disease from initial infection to the death of the patient 
is about two to ten years, while the duration of the more virulent 
Rhodesian form is only six to nine months. In the latter disease, 
there is less demarcation between the early and advanced stages of the 
infection, and the somnolence and other signs of nervous damage are 
rarely seen (Apted, 1970). 
1.2.3 African Animal Trypanosomiases 
Animal trypanosomes particularly in cattle, are a major 
restraint on meat production in Africa. Four million square miles of 
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the African continent is infested with the tsetse fly (Buxton, 1955) 
and productive cattle cannot be kept within that area owing to the 
threat of trypanosomiasis (Willet, 1970). Wilson et al (1963) has sug~ested 
that if the tsetse fly were eradicated, the total head of cattle would 
be doubled. This would not only improve the nutrition of the African 
people, but also encourage the spread of agriculture by providing 
draught animals for ploughing. However, the eradication of the tsetse 
fly would not necessarily eradicate the disease, because the major 
pathogenic species (T. congoZense; T. vivax) are known to be also 
transmitted by mechanical inoculation (Hoare, 1970). 
In addition, Ormerod (1976; 19 70 has argued that elimination of 
trypanosomiasis would be accompanied by overstocking of cattle, leading 
to ecological degradation (soil erosion) particularly in the Sahel 
region south of the Sahara; thus encouraging desertification. In 
contrast, Na'isa (1977) considers that as diseased animals are 
unproductive, trypanosomiasis encourages overstocking and, consequently, 
elimination of disease would solve this problem. 
Cattle trypanosomiasis is primarily caused by T. congoZense, 
T. vivax and T. bpucei. Wild game serve as reservoirs for these 
trypanosome (Willet, 1970) and, as with T.b. rhodesiense, the 
trypanosomiases do not produce disease in their reservoir hosts 
(Ashcroft et al., 1959). T. aongoZense and T. vivax are the most 
important cause of nagana. The symptoms of the disease are mild fever, 
wasting and anaemia (Stephen, 1970). Death can occur within three 
weeks of infection with a virulent strain, although less virulent strains 
can cause chronic disease from which the animal spontaneously recovers 
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Cattle tolerate infection with T. brucei and recover spontaneously, 
although the infection is fatal to horses, with death usually occurring 
several months after the initial infection. 
T. evansi is the causative agent of surra, a disease of camels and 
horses which is prevalent throughout Southern Asia, South America and 
Africa north of the Sudan zone (Hoare, 1970). This trypanosome is closely 
related to T. brucei, from which it is thought to have evolved (Hoare, 
1970), but has lost the ability to be transmitted by the tsetse fly. 
The disease is transmitted by mechanical inoculation by biting tabanid 
flies (Hoare, 1970). 
T. vivax and T. congolense can also be transmitted by mechanical 
inoculation, thus enabling them to exist outside the range of the tsetse 
fly. T. vivax has been found 1n Mauritius (Boare 1970 ), the Caribbean 
(Hoare 1970 ), and in South America (Shaw and Lainson, 1972). 
1.2.4 Life cycle of the salvarian trypanosomes (see Figure 1.1) 
Trypanosomes (trypomastigote form) are ingested by the tsetse fly 
with its blood meal when it feeds on infected animals. The parasites 
undergo a series of changes within the fly during the next 17-45 days 
(Hoare, 1970). The parasite rapidly multiples in the mid-gut of the 
fly, and gradually migrates towards the tsetse fly mouth parts. 
Eventually the parasites reach the salivary glands, where they become 
attached to the wall of the gland and multiply further as the 
epimastigote form. Twenty to thirty days after ingestion, metacyclic 
forms appear and these are infective to the mammalian host (Hoare, 1970). 
Metacyclic forms are injected into the bloodstream of an animal on which 
the fly is feeding along with salivary secretion. After the subcutaneous 
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deposition, the trypomastigotes multiply and invade blood, lymph and 
tissues. Subsequently, the infection spreads to all tissues although, 
initially, the parasites do not seem able to reach or maintain 
themselves in the cerebro-spinal fluid (Apted, 1970). Three forms of 
trypomastigote develop in the bloodstream of the infected animal; 
long slender forms, intermediate forms and short stumpy forms. The 
short, stumpy form is believed to be the form which infects the tsetse 
fly (Vickerman, 1965). 
The life cycle of T. congoZense is slightly different in that the 
epimastigote and infective trypomastigote forms develop in the 
proboscis of the fly rather than the salivary glands, and the bloodstream 
form of the trypanosome is not pleomorphic (Hoare, 1970). 
Trypanosoma vi vax follows a different life cycle, as all of the 
development changes occur in the proboscis of the fly (Hoare, 1970). 
This trypanosome is often transmitted mechanically by biting flies and 
the parasites probably do not undergo developmental changes in this 
case. The bloodstream forms of T. vivax are monomorphic although 
virulent strains tend to be shorter than less virulent strains 
(Fairbairn, 1953). 
Different developmental stages in the life cycle of trypanosomes 
have markedly different morphology and biochemical activity. In 
T. brucei the long slender forms of the parasite which are found in 
the vertebrate host have a DNA containing kinetoplast continuous with 
a simple mitochondrion containing almost no cristae and energy 
production is by glycolysis. When the trypanosome changes into the 
short stumpy form, which is infective to the tsetse fly, the 
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Figure 1.1: Life cycle of the T. bruaei subgroup of trypanosomes 
(Vickepnan, 1965). 
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a nreadaption necessary for sunTival in the i'1sect Mid-sut. Once in 
the tsetse mid-eut energy prorillct;"n is by a citric acid cycle and a 
respiratory cytochrome chain (Vickerman, 1965). 
An appreciation of the life cycle and biochemistry of the 
trypanosornes and the differences between host and parasite biochemistry 
is of fundamental importance in the rational design of trypanocidal 
drugs since these differences can be targets for chemotherapeutic 
attack. 
1.2.5 American Human Trypanosomiasis 
American human trypanosomiasis is caused by the stercorarian 
trypanosome T. (schizotrypanum) cruzi. The parasite was originally 
discovered by Carlos Chagas in Brazil (Lewinsohn 1979). The parastite 
has since been found in most countries of South America and as far 
north as Texas, USA. 
It is difficult to assess the prevalence of the disease. The 
World Health Organisation (1967) estimate of seven million people 
infected is probably an underestimate, and the true figure is thought 
to be nearer 13-14 million (Zeledon and Rabinovich 1981). 
The disease was originally a zoonosis and is prevalent 1n many 
wild and domesticated animals (Zeledon, 1974). Some of the insect 
vectors have become adapted to a domestic environment, and so the 
disease has spread to man (Zeledon and Rodriguez, 1981). The disease 
is transmitted by haematophagous triatomine bugs (Reduviidae family) 
which infest man's dwelling places. Transmission usually occurs 
through contamination of a wound or abrasion with excrement from an 
infected vector. Other modes of transmission have been discovered, 
such as congenital (Howard, 1962), through blood transfusion 
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or by contaminated food (Brener, 1971). 
Many accidental infections of laboratory workers concerned with this 
parasite have also been recorded (Hawking, 1963). 
1.2.6 Clinical features of Chagas disease 
Chagas' disease is characterised by an acute and a chronic phase, 
although identification of patients with the acute phase is relatively 
rare even in endemic areas (Marsden, 1971). The acute phase is 
characterised by trypanosomes in the blood which are detectable by 
microscopic examination· Onset of symptoms begins 
about ten days after the initial infection and trypanosomes can be 
detected after about two to four weeks (Marsden, 1971). The acute phase 
lasts from six to ten weeks and is characterised by fever, oedaema, 
lymphadenopathy and cardiac irregularities (Brener, 1971). Ninety per 
cent of patients survive the acute phase, but it is doubtful whether 
their infection is ever eradicated (Marsden, 197 1). 
After one to two months, the parasitaemia subsides and the patient 
enters the chronic phase of the disease. During the chronic phase, the 
disease is asymptomatic in the majority of patients. Those patients who 
do manifest the disease overtly usually present one of two clinical 
symptoms which are chronic chagasic cardiomyopathy and the mega syndrome 
(Marsden, 1971). In chronic chagasic cardiomyopathy the heart is enlarged 
and cardiac contractions are weak. Intractable heart failure and sudden 
death associated with acute cardiac arrest, or ventricular fibrillation, 
are common (Marsden, 1971). The mega syndrome is caused by dilation 
of hollow muscular organs, such as the oesophagus and 
colon (Koberle, 1974). Although not commonly a cause of death, these 
deformations cause serious discomfort to the patient. The pathogenesis 
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of both forms could be related to the destruction of nerve cells in the 
gut and cardiac autonomic nervous system (Koberle, 1974), due to the 
formation of intracellular amastigote forms of the parasite. 
Trypanosoma cruzi differs fundamentally from the African 
trypanosomes in many respects. These include mode of transmission, 
vectors, life cycle (especially intracellular invasion) and bio-
chemistry. As this thesis is concerned with T. rhodesiense, a 
causative agent of sleeping sickness, discussion of T. cruzi will 
be included only where it is relevant. 
1.3 Chemotherapy of Trypanosomiasis 
Atoxyl (Figure 1.2) was the first successful trypanocidal drug to 
be introduced~ It was found to be effective 
in early Gambian sleeping sickness, but although its use was sometimes 
followed by ocular atrophy, it did provide hope to sufferers from this 
previously incurable disease. The success of Atoxyl led its originator, 
Paul Ehrlich, to prepare a series of homologues leading to the 
discovery of salvarsan and ultimately 
tryparsamide (Figure 1.2) (T.lillia!!lson, 1970). 
Tryparsamide was the first effective dru~ against the advanced stage 
of Gambian sleeping sickness and was the drug of choice for nearly 
50 years after its introduction. 
By 1950, arsenical resistant T.b. gambiense was widespread, and 
about 80% of late stage infections in the Congo were resistant to 
tryparsamide (Friedheim, 1949). Tryparsamide was superseded by the 
melaminyl series of arsenical drugs which were developed by Friedheim 
and based on the structure of the parent drug melarsen (Friedheim, 1941), 
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(Figure 1.2). Despite reports of toxicity, melarsen was soon followed 
by melarsoprol (Mel B), melarsonyl potassium (Mel W) and the antimony 
analogues MSb and MSb B (Williamson, 1970). 
Of these drugs, melarsonyl has become firmly established in the 
treatment of Rhodesian sleeping sickness while melarsen and melarsonyl 
potassium are still used in parts of West Africa (Apted, 1970). 
Melarsoprol has proved effective against tryparsamide resistant Gambian 
and Rhodesian sleeping sickness at all stages of the disease (Van Hoof, 
1947; Apted, 1953) and after its introduction in Tanzania, the death 
rate dropped from over one third to 10% of those who contracted 
sleeping sickness (Apted, 1957). 
As well as development of the organic arsenical drugs, Paul Ehrlich 
was also interested in the use of organic dyes as potential trypanocides 
(Williamson, 1970). This line of enquiry stemmed from the observation 
that methylene blue, a cytochemical stain which was taken up avidly 
by the malaria parasite was also cytotoxic. 
Following this discovery, Ehrlich tested many different dyes and 
eventually found one sulphonated azo dye: trypan red, which was both 
curative and prophylactic (Williamson 1970) in the treatment of 
trypanosomiasis. Modification of trypan red produced other compounds 
of greater activity, although none came into field use. Following from 
Ehrlich's work, chemists at Bayer in Germany prepared analogues closely 
related to Ehrlich's dyes, and their work culminated in the discovery 
of suramin (Bayer 205, Germanin) in 1916 (Williamson, 1970). 
Suramin (Figure 1.3) is effective against the early forms of both 
Gambian and Rhodesian sleeping sickness with a cure rate of almost 
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Figure 1.3: Structure of ~ramin, diamidine and phenanthridinium drugs 
cerebro-spinal fluid and is of no use once the infection has reached 
the central nervous system, although it will clear trypanosomes from 
the blood and render the patient non-infective. Suramin combines 
with blood proteins and is excreted very slowly. A single injection 
of one gram will maintain a blood concentration sufficient to provide 
protection from infection for several months (Apted, 1970) •. 
The trypanocidal activity of the diamidine series of drugs was 
discovered independently by Jancso and Jansco and Shern and 
. 
Arlagaveytia-Allende 1n 1935 who observed that the aliphatic 
diguanidine synthalin, an insulin substitute, was trypanocidal in vivo. 
Further work by King et al. (1937) , and May and Baker Ltd., produced 
several active aromatic diamidine derivatives, of which only pentamidine 
and berenil (Figure 1.3) have come into field use for trypanosomiasis. 
Pentamidine is a valuable drug for the treatment of early sleeping 
sickness and particularly as a prophylactic. A single dose of 300 mg 
will give complete protection for six months (Waddy, 1970). Berenil 
(diaminazene aceturate) is active against sleeping sickness, but is 
licensed only for veterinary use and is important in the treatment of 
nagana. Unlike pentamidine, berenil is rapidly excreted, usually 
within twenty-four hours of treatment. Although there is evidence 
that some of the drug is retained in the tissues (Williamson 1970) 
the rapid excretion of berenil is thought to lessen the risk of 
resistance developing through exp~sure to a waning concentration of 
drug; it also reduces the likelihood of chronic toxicity (Leach and 
Roberts, 1981). 
The phenanthridinium drugs (Figure 1.3) were introduced by Morgan 
and Walls in 1931). Dimidium showed high activity against infections 
in cattle due to T. vivax and T. aongolense (Williamson, 19 62), but 
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treatment was often followed one to two months later, by severe toxic 
photosensitization and liver lesions. Ethidium, which differs from 
dimidium by having an ethyl group in place of a methyl group on the 
quarternary nitrogen atom, was as effective, and much less toxic (Leach 
and Roberts, 1981). Following the success of ethidium, other 
phenanthidinium drugs, most notably prothidium (Watkins and Hoolf, 
1952), metamidium and isometamidium (Wragg et al., 1958), have been 
introduced. No new trypanocide for human or veterinary use has been 
introduced since Mel Band metamidium, although research has continued. 
Williamson (1976) attributes this situation to the high cost involved 
in developing and marketing new drugs for countries which have low 
drug budgets, and are of uncertain economic stability. The World 
Health Organisation is attempting to overcome this problem by providing 
support for research through the Special Programmes for Research and 
Training in Tropical Diseases 
The need for new drugs for the treatment of trypanosomiasis is 
becoming more urgent as reports of drug resistance and problems of 
drug toxicity become more widespread. Trypanosome strains resistant 
to each of the main classes of drug and in some cases cross-resistant 
to several drug classes, have been reported (Williamson, 1976). 
De Raadt (1975) reported the appearance of a strain of T.b. rhodesiense 
which is resistant to melarsoprol. Many of the drugs currently in use, 
like melarsoprol, have a low therapeutic index, and the use of higher 
doses to combat resistance may be attended by toxic reactions. For 
example, melarsoprol, which is vital for the treatment of advanced 
Rhodesian sleeping sickness, causes fatal haemorrhagic encephalopathy 
in about 1% of patients when a standard dose is given (Apted, 1970). 
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It is thus too toxic to treat resistant strains, and alternative 
treatment, such as nitrofurazone, is also a toxic hazard. 
1.3.1 Development of new trypanocidal drugs 
Over the previous twenty years, three methods of research into 
new trypanocidal drugs have emerged. These are by (i) modification 
of existing drugs; (ii) empirical screening, and by (iii) rational 
consideration of the biochemical differences between parasite and host. 
1.3.1(a) Modification of existing drugs 
The organic arsenicals and the diamidines have provided many 
compounds of high intrinsic activity. Recently, Dann and co-workers 
have synthesized a series of diamidines (Dann et al., 1970; 1971; 
1Q72; of which one, 6-amidino-2(4-amidinophenyl)-indole 
(DAPI) (Figure 1.4) has activity equivalent to berenil in experimental 
infections. However, resistance to one 
diamidine confers resistance to other drugs in the series and berenil 
resistant trypanosomes are also resistant to DAPI (Williamson, 1976). 
The possibility of cross-resistance to different drugs of the same 
type is a major weakness in this method of seeking new drugs. Many 
of the drugs now in use, such as metamidium, have been developed by 
combining portions of known trypanocides. This process of 'hybrid 
synthesis' (Williamson, 1962) is thought to favour the development of 
cross-resistance between drugs of different classes (Leach and Roberts, 
1981). 
1.3.1(b) Empirical Screening 
This approach has revealed many new trypanocidal compounds 






Figure 1.4: D.A.P.I. (6-amidino-2(4-amidinophenyl)-Indole 
- 20 .. 
ancantibiotics from Streptomyces species (Kinnamon et al., 1979; 
Williamson and Scott-Finnigan, 1975). A number of purine 
nucleoside analogues of adenosine, including puromycin and cordycepin 
(Figure 1.4) possess both antitumour and trypanocidal activity. This 
trypanocidal activity is significant as pathogenic African trypanosomes 
are unable to synthesise the purine ring and are dependent on their 
host for a source of preformed purine (Gutteridge and r.aborak 1979) 
One such analogue, puromycin (Figure 1.5) has been tested clinically 
and found to be effective in the early stage of sleeping sickness, 
but not when the central nervous system is involved (Williamson 1962) 
~etabolic analogies between pathogenic trypanosomes and rapidly 
dividing tumour cells are reflected in their similar sensitivity 
to drugs. Kinnamon et ale (1979) tested a range of 49 antitumour 
dru~s against T.b. rhodesiense in vitro and found that six 
structurally unrelated drugs were trypanocidal; a higher proportion 
than would be ex~ected by chance. 
1.3.1(c) Rational approach 
The lack of discovery of new drugs during the past twenty-five 
years has encouraged an investigation of the biochemistry of 
trypanosomes in order to identify and exploit the biochemical differences 
between parasite and host. Trypanosomes of the T. brucei subgrou~ for 
example, show marked biochemical differences from the mammalian host. 
The bloodstream forms of T. brucei lack catalase (Fulton and Spooner, 
1956), a tricarboxylic acid cycle, and enzymes involved in the 
biosynthesis of fatty acids (Bowman and Flynn, 1976). They also 
contain enzymes of unusual properties, such as a glycerol phosphate 











Figure 1.5: Trypanocidal nucleoside antibiotics 
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insensitive to cyanide, but is inhibited by salicyl hydroxamic acid 
(Fairlamb and Bowman, 1977). Following a study of the metabolism of 
the bloodstream form of T. brucei, Clarkson and Brohn (1977) discovered 
that S.H.A.M. in combination with glycerol totally inhibited trypanosome 
glycolysis and was trypanocidal in vivo. The development of this 
trypanocidal drug combination would not have been detected in a 
conventional screen for trypanocidal drugs, as neither compound is 
trypanocidal on its own. 
Trypanosomes are more susceptible to damage by reactive oxygen 
species than mammalian cells, as they do not possess catalase, which 
destroys hydrogen peroxide. To exploit this lesion, Meshnick et ale 
(1978) have demonstrated that haematoporphyrin, a compound which 
catalyses the homolytic cleavage of hydrogen peroxide via a Fenton type 
reaction to form the highly reactive hydroxyl radical, is trypanocidal 
in vivo. Another vulnerable target for chemotherapy is polyamine 
metabolism. Biosynthesis of polyamines in trypanosomes is thought to 
occur as with other cells by conversion of ornithine into putrescine 
by a decarboxylation reaction, then to spermidine and spermine by 
sequential addition of an aminopropyl group (Bacchi, 1981). The 
synthesis of polyamines in T. brucei can be inhibited by a difluoro-
methyl ornithine (D.F.M.O.). Administration of a 2% solution of D.M.F.O. 
in drinking water cured mice infected with T. brucei (Bacchi, 1981). 
Although none of the trypanocides discussed above has so far come 
into field use because of impracticality or toxicity, these examples 
illustrate that the rational approach to the design of drugs has 
considerable potential for discovering new trypanocides. 
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1.4 The anthracycline antibiotics 
The anthracyclines are a group of antibiotics produced by various 
Streptomyces spp. Their name is based upon their structural features 
they contain an anthraquinone chromophore within a hydrocarbon skeleton 
related to that of the tetracyclines. Anthracyclines occur naturally 
as glycosides or as aglycones known as anthracyclinones. 
The first clinically effective anthracycline - daunorubicin 
(Figure 1.6,was isolated independently in 1963 from Streptomyces peucetius 
by Casinelli and Orrezi and from Streptomyces coeruleorubidus by 
Du Bost et al. Daunorubicin has few clinical indications, but has 
achieved a s~gnificant role in the treatment of acute lymphocytic 
leukaemia and acute non-lymphocytic leukaemia (Bernard et al., 1969). 
Doxorubicin (Figure 1.6), a closely related antibiotic, was isolated 
from a mutant strain of Streptomyces peucetius (Arcamone, 1969 ); it 
is active against a wide spectrum of solid tumours, some of which 
were previously insensitive to chemotherapy (Carter, 1975). Doxorubicin 
has become established as one of the most clinically important anti-
tumour drugs. 
The anthracyclines are highly toxic, particularly to rapidly 
dividing tissues, and cause alopecia, stomatitis, myelosuppression and 
leukopaenia. The usefulness of daunorubicin and doxorubicin is limited 
by an irreversible and often fatal dose-related cardiomyopathy 
(Minow et al., 1975). 
Although daunorubicin and doxorubicin differ only by the presence 
of a hydroxyl group at the C-14 position, they are clearly 
distinguishable at the cellular and clinical levels (Di Marco et al., 
1974). The observation that a small modification in the chemical 
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Figure 1.6: Structure of Daunorubicin, 5-Iminodaunorubicin 
and Doxorubicin. 
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properties of the drug has prompted the search for new anthracyc1ine 
analogues with improved antitumour action and reduced cardiotoxicity. 
The main approach to the development of the anthracyc1ine antitumour 
agents has been by chemical modification of the active anthracyc1ines 
(Arcamone, 1977; Brown, 1978). This approach has produced drugs with 
similar potency, but reduced cardiotoxic properties compared with 
daunorubicin and doxorubicin. Two examples of this approach are 
5-iminodaunorubicin and N,N-dibenzy1daunorubicin (Acton et a1., 1981). 
Other important areas of research have been the isolation of new 
anthracyclines from microorganisms (Nettleton et a1., 1980), and the 
development of synthetic anthraquinone analogues modelled on daunorubicin 
(Brown, 1983). 
1.4.1 Anthracyc1ines as trypanocidal agents 
These developments in anthracycline chemistry may be of importance 
to the chemotherapy of trypanosomiasis because of the established 
parallel between antitumour and trypanocidal activity (Kinnamon et al., 
1979). The first demonstration of anthracycline activity against 
trypanosomes was the isolation by Fleck et ale (1972) of the 
anthracycline trypanomycin, which possesses trypanocidal activity 
against T.b. bruaei in mice. The in vitro trypanocidal activity of 
the anthracyclines was also demonstrated by Williamson and Scott-Finnigan 
using T. aongoZense (1975), T.b. bruaei and T.b. rhodesiense (1978). 
All of the anthracyclines tested were active, although daunorubicin was 
unique in being ranked, with nucleocidin, as one of the most potent 
trypanocides known (Williamson and Scott-Finnigan, 1978). Unfortunately, 
these workers showed both doxorubicin and daunorubicin to be inactive 
in vivo (Williamson et a1., 1981). 
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1.4.2 Mechanisms of anthracycline cytotoxicity 
Daunorubicin and doxorubicin are known to have many different 
cellular effects, but the major cytotoxic effect is thought to be 
inhibition of nucleic acid synthesis by interaction with nuclear DNA. 
This view is supported by a large body of data; for instance, auto-
radiographical and fluorescence quenching experiments which have shown 
that daunorubicin is concentrated in the nucleus of normal (rat liver) 
and tumour cells in culture (Bernard et a1., 1969). 
Daunorubicin and doxorubicin bind to DNA by a process of 
intercalation whereby the flat anthraquinone moiety inserts between 
adjacent base pairs (Figure 1.7) so that the D ring of the daunorubicin 
chromophore protrudes into the major groove of the DNA double helix 
(Quigley et al., 1980). 
Intercalation of the drug into DNA causes changes in the properties 
of both DNA and rug which may be used to study the interaction. Upon 
intercalation, the adjacent base pairs move apart to accommodate the 
drug molecule. The resulting local distortion is relieved by a local 
unwinding of the double helix and a slight lengthening of the DNA 
molecule (Freifelder, 1971). 
The anthracyc1ines, in common with other intercalating agents, 
such as lucanthone and ethidium, produce double and single stranded 
DNA breaks (Kohn and Zwelling, 1981). These strand breaks do not 
appear to be significant for cytotoxicity as Zwelling et al. (1982) 
found no positive relationship between cytotoxicity and production of 
strand breaks for the anthracyc1ines doxorubicin and 5-iminodaunorubicin. 
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Figure 1.7: Intercalation of drug into the DNA double helix~ 
(a) and (b) represent DNA before and after 
intercalation. 
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Daunorubicin and doxorubicin can also cause DNA strand scission 
through catalysing the formation of the superoxide anion. In the 
presence of NADPH and either microsomes or isolated nuclei, 
daunorubicin is reduced to the semiquinone anion CBachur et al., 
1978; 1982). The reduced anthraquinone moiety can then reduce 
molecular oxygen to the superoxide anion (Goodman and Hochstein, 
1977) according to the following redox couple: 
AQ~ 
° ~ 2 
Detection of the semiquinone anion in culture cells treated with 
daunorubicin indicates that a similar process may occur in vivo 
Sato et al., 1977). 
Hydrogen peroxide can be formed intracellularly by spontaneous 
dismutation of superoxide anion, or by the action of the enzyme 
superoxide dismutase (S.O.D.) 
0· 
2 
+ + Superoxide ~d~i~s-m-u~t~a~s-e----~> H202 
+ 
Production of superoxide and hydrogen peroxide can lead, by a 
chelated iron catalysed reaction, to the generation of the highly 




------~----~> OH· + catalyst OR + 
The hydroxyl radical is known to cause DNA strand scission 
(Lesko et al., 1980). However, since intercalating agents which do 
not catalyze the formation of reactive oxygen species also cause 
DNA strand breaks, other mechanisms of strand breakage may be 
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important (Zwelling et al., 1982). The hydroxyl radical can also be 
formed by a reaction between hydrogen peroxide and the doxorubicin 
semiquinone anion (Winterborne, 1981), thus obviating the requirement 
for molecular oxygen. This mechanism of hydroxyl radical formation 
may be important in trypanosomes, since they are known to possess 
high intracellular concentrations of hydrogen peroxide (Meshnick et a1 1977) 
Bachur et ale (1982) has postulated that the semiquinone radical 
is formed in the nucleus and DNA damage occurs on intercalation. 
The observation that chemically reduced d~unorubicin binds DNA 
supports this mechanism (Sinha and Chignell, 1979). However, DNA 
cleavage by chemically reduced daunorubicin is partially inhibited 
by superoxide dismutase and catalase (Lown et al., 1977), indicating 
a role for the superoxide anion, hydrogen peroxide and/or hydroxyl 
radical. 
In addition to DNA damage, the free radical species produced 
by anthracycline redox cycling may attack other intracellular 
targets. Administration of daunorubicin or doxorubicin is accompanied 
by a dramatic increase in microsomal lipid peroxidation (Goodman and 
Hochstein, 1977; Mimnaugh et al., 1981a). Lipid peroxidation is 
the free radical mediated degradation of unsaturated lipids which 
results in the formation of a variety of lipid peroxidation products, 
including alkanes and various aldehydes, including the 4-hydroxy-
alkenals and malondialdehyde (Esterbauer, 1982), (see Figure 1.8). 
The potential cytotoxic effects of lipid peroxidation include loss 
of integrity of lipid membranes, disintegration of the endoplasmic 
reticulum and mitochondrial membranes (Hogberg et a1., 1973; 
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Figure 1.8: Schematic representation of anthracycline induced lipid peroxidation 
enzymes (Mimnaugh et al., 1981b), and damage to nucleic acid 
(Summerfield and Tappel, 1981). 4-Hydroxyalkenals produced during 
lipid peroxidation are known to react readily with proteins containing 
thiol and amino groups (Esterbauer 1982), and this might contribute 
towards the cytotoxicity of the anthracyclines. Malondialdehyde in 
particular is a known genotoxic agent produced during lipid 
peroxidation, and as a product of free radical attack on DNA 
(Gutteridge, 1979), can also cause DNA damage (Bird et al., 1982). 
Lipid peroxidation has been implicated as a cause of the 
myocardial toxicity associated with the clinical use of daunorubicin 
and doxorubicin. Studies with animal models have shown that 
administration of doxorubicin is associated with perturbations of 
the intracellular antioxidant control systems, including decreases 
in glutathione (Olsen et al., 1977), glutathione peroxidase and 
selenium levels (Revis and Marasic, 1978). Conversely, endogenous 
administration of radical quenching agents, such as ubiquinone 
(Choe et a1., 1979), a-tocopherdl (Myers et a1., 1977) and superoxide 
dismutase with catalase (McGuinness et al., 1979) protect against 
this myocardial toxicity. Cardiac tissue is believed to be 
particularly at risk from lipid peroxidation as it is deficient 1n 
two important enzymic defences relative to other organs. Superoxide 
dismutase activity in rat heart is about 20% of the activity of rat 
liver (Van Hien et a1., 1975) and rat heart catalase activity is 2% 
of rat liver catalse activity (Thayer, 1977). 
Reactive oxygen species may play an important role in the 
trypanocidal activity of the anthracyclines, as they lack important 
enzymie defences against active oxygen species Trypanosoma cpuzi 
and ~panosoma b. brucei both lack catalase (Boveris and Stoppani, 
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1977 ; Fulton and Spooner, 1956), and glutathione peroxidase (Boveris 
et al., 1980; Meshnick et al., 1978), although T. cruzi does contain 
superoxide dismutase (Boveris and Stoppani, 1977) and an ascorbate 
linked peroxidase with low activity (Docampo et al., 1976). However, 
intracellular concentrations of hydrogen peroxide are much higher in 
trypanosomes than in mammalian cells. Meshnick et ale (1977) have 
reported an intracellular concentration of 70 mM in T.b. brucei 
which is approximately thirty times that found in rat liver. This 
apparent metabolic weakness of trypanosomes has been exploited by 
Meshnick et ale (1977), who showed that haematoporphyrin, a compound 
which catalyses the homolytic cleavage of hydrogen peroxide to the 
highly active hydroxyl radical, was curative for T.b. brucei 
infections in mice. 
The trypanocidal activity of S-lapachone and nifurtimox, two 
drugs which are active against T. cruzi was thought to be due to drug 
induced production of superoxide anions, and hence hydrogen peroxide 
(Docamps et al. (1978, 1981) which might 
accumulate to cytotoxic levels since T. cruzi does not contain catalase. 
However, the sensitivity of the catalase containing trypanosomatid 
Crithidia fasciculata tonifurtimox is incompatible with this mechanism 
of action (Gutteridge et al., 1982). However, Crithidia fasciculata 
is insensitive to S-lapachone (Lopes et al., 1978). 
The anthracyclines have other mechanisms of cytotoxicity in 
addition to those discussed. Recently, Tritton and Yee (1982) and 
Tokes et al. (1982) have shown that doxorubicin does not need to 
enter the cell in order to exert a cytotoxic effect. The mechanism by 
which this cytotoxicity occurs is unknown at present, although 
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doxorubicin has previously been shown to exert various effects on the 
cell membrane. These have included effects on phospholipid structure, 
membrane fluidity, transport of small molecules and expression of 
hormone and lectin receptors (Tritton and Yee, 1982). 
1.5 The targeting of chemotherapeutic agents 
The chemotherapy of both cancer and parasitic diseases has been 
compromised by the toxicity of the available drugs. A major problem 
is the lack of specificity of the drug for the target cell. This, 
as well as the lack of progress in developing new antiparasitic 
drugs, has stimulated research into ways of improving the therapeutic 
index of existing drugs. Considering tumour cells, metabolic differences 
between these and normal cells are frequently quantitative, rather 
than qualitative: the action which produces a desired effect in the 
tumour, will also produce severe toxicity to normal cells. Hence, 
the optimum dose of an antitumour agent is often a compromise between 
sub-optimal therapeutic effects and tolerable toxic effects (Poznansky 
and Cleland, 1979). Similarly, many of the antiparasitic drugs, such 
as the arsenicals and antimonia1s, also produce severe toxic effects 
which limit their clinical usefulness (Apted, 1970). 
Improvement of the therapeutic index of existing drugs can be 
approached in several ways: (i) preparation of analogues by formation 
of a pro-drug with enhanced uptake properties for the target cell 
and/or greater metabolism of the pro-drug in the target cell compared 
with normal cells; (ii) binding of drug to macromolecular carrier; 
(iii) entrapment of free drug in an encapsulation carrier. 
- 34 -
1.5.1 Pro-drugs 
In order to rationally design a pro-drug, the biochemical and 
morphological characteristics of the target cell must be known so 
as to exploit differences between these cells and normal cells, and 
the choice of pro-drug derivative is also limited by the functional 
groups present in the parent drug which are suitable for derivatization. 
As regeneration of the parent drug is required, the choice of 
derivative is usually limited to groups possessing enzymic, or 
chemical lability, such as peptides and esters. 
An example of the rational design of a pro-drug 1S a peptide 
derivative of phenylene-diamine mustard which Carl et al. (1980) 
have shown to be selectively hydrolysed by tumour cells to the parent 
drug. 
An example of pro-drug design applied to the anthracycline 
series is rubidazone, a benzoyl hydrazone derivative of daunorubicin 
in vivo (Baurain et al., 1979). 
Another example of pro-drug design applied to the anthracyclines 
is a series of peptide derivatives of daunorubicin developed by 
Masquelier et al. (1980). These pro-drugs were metabolised to 
daunorubicin by lysosomal peptidases, but were more active than 
daunorubicin against L1210 leukaemia in vivo (Baurain et al., 1980). 
1.5.2 Macromolecular conjugates 
The use of macromolecules to target drugs was first proposed by 
Paul Ehrlich in 1906 who predicted the existence of antibodies and 
foresaw their use as drug carriers. Macromolecules were first used 
as drug carriers by Mathe et al. (1953) who demonstrated the 
enhanced antitumour activity of methotrexate when covalently bound 
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Figure 1.9: Pro-drug specifically activated by tumour 
associated enzymes (Carl et al., 1980) 
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Figure 1.10: Rubidazone - a daunorubicin pro-drug 
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to tumour-specific antibodies. Subsequently, a variety of macro-
molecular carrier systems have been developed, both with and without 
specific affinity for the target cell. These have included 
macromolecules such as antibodies (Hurwitz et al., 1975), lectins 
(Kitao and Hattori, 1977; Lin et al., 1981) and hormones (Varga et al., 
1977; Kaneko, 198 1) which have specific affinity for the target 
tissues, albumin (Trouet et al., 1982) and dextran (Levi-Schaffer 
et al., 1982) which have no such affinity. As well as improving drug 
uptake into the target tissue, carriers have been used to enhance 
a variety of desirable characteristics of drugs and enzymes used ~n 
therapy. L-Asparaginase, an enzyme used in the therapy of acute 
lymphocytic leukaemia, is rapidly inactivated in vivo as well as 
producing a severe immunogenic side effect characterised by 
anaphylactic shock. Serum albumin has also been used as a 
drug carrier to reduce the rate of drug clearance from the 
body (Poznansky and Cleland, 1980). The formation of a 
non-covalent drug-albumin conjugate is an important factor 
in explaininp the slow plasma clearance and the profylactic 
activity of the trypanocidal drug suramin (Goldstein, 1949). 
1.5.2(a) Mechanism of action of drug-macromolecule conjugate 
The carrier requirements of different therapeutic agents will 
vary widely and, in practice, no carrier system will satisfy the 
requirements of a broad spectrum of drugs and enzymes. However, 
there are certain characteristics that must be considered in the 
rational design of an 'ideal' carrier. The primary.requirement of 
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a carrier used for targeted antiparasitic chemotherapy is that it 
should reach the target tissue without breakdown, or inactivation, 
by plasma enzymes. Uptake by host tissues should be minimal and the 
carrier should not elicit an 1mmune response. 
Once transported to the vicinity of the target cell, the drug 
carrier conjugate may exert its effects in several ways. The first 
possibility is that the drug might be cleaved by degradative enzymes 
in the extracellular fluid, allowing free drug to permeate into the 
cell. This mechanism might well be important in cancer chemotherapy 
as lysosomal enzymes have been detected on the surface of tumour 
cells (Naoy et al., 1977) and in necrotic tumour areas (Strauli and 
Weiss, 1977). Another possibility is that the intact drug-carrier 
complex may enter the target cell by endocytosis, after which the 
endocytic vacuole fuses with a lysosome to form a secondary lysosome. 
The drug is released by lysosomal hydrolysis and may diffuse through 
the cytoplasm to its intracellular target. This mechanism has been 
studied by Deprez-De Campaneere et al. (1979) who demonstrated that 
the mechanism was valid for the release of drug from the doxorubicin-
DNA complex. 
Weisenhahn et a1. (1981) showed inhibitors of endocytosis 
decreased the toxicity of daunorubicin-melanotropin conjugate for 
mouse melanoma cells, and also showed that the conjugate did not 
interact with DNA in vitro, which suggests that intracellular release 
of daunorubicin is necessary for activation of this conjugate. 
The drug carrier complex may act intracellular1y without 
preliminary drug release. At present there is little to support 
this hypothesis, but Hurwitz et a1. (1975) have reported that 
daunorubicin linked to antibody can interact with DNA, and Lewis 
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ct al. (1974) have shown that, following pinocytosis antibodies can 
be found associated with nucleus of human lymphocytes. The idea that 
anthracycline conjugates can be active in their own right has recently 
received support from the work of Tritton and Yee (1982) who showed 
that doxorubicin-linked macromolecules could exert cytotoxic effects 
without entering the cell. 
1.5.2(b) The use of anthracycline-macromolecule conjugates 
The use of anthracycline-macromolecule conjugates in the treatment 
of cancer was proposed by Trouet et al. (1972) who studied the use 
of daunorubicin-DNA and doxorubicin-DNA conjugates in the treatment 
of tumours possessing a high rate of endocytosis. Animal studies 
(Deprez-De Campaneere, 1979) have shown that these DNA conjugates 
are superior to the free drugs in the treatment of several different 
types of tumour. 
A major obstacle to the widespread use of DNA conjugates is that 
they lack tissue specificity and are taken up by ceLls possessing a 
high rate of endocytosis. In order to overcome this problem, 
Hurwitz et ale (1975) have systematically studied covalently bound 
anthracycline-antibody conjugates. All of the conjugates tested 
possessed antitumour activity, but conjugates containing a high 
loading of drug had reduced antibody activity. The loss of activity 
which accompanies the formation of antibody conjugates has been a 
major problem in using antibodies as drug carriers. In an attempt 
to increase the amount of drug bound while retaining antibody 
activity,Bernstein et ale (1978) linked daunorubicin to dextran prior 
to linking the complex to antibody. This procedure allowed a five-fold 
increase in the amount of drug bound per conjugate molecule compared 
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Extracellular F IUlCl 
Figure 1.11: Modes of action of a drug-carrier complex. 
(Poznansky and Cleland 1979). 
The drug can enter the cell either by simple diffusion following . 
extracellular release from the carrier or endocytosis of the drug-
carrier complex. Once inside the cell, drug may be released from 
the drug-carrier complex by the action of lysosomal hydrolases. 
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to that linked to antibody alone. However, when tested in vivo the 
drug antibody conjugate had no therapeutic advantage over the 
equivalent dose of free drug, but was more active than drug bound to 
a non-specific immunoglobulin. The best results were obtained when 
drug and antibody were given simultaneously. This drug-antibody 
synergism has been noted with other drugs (Ghose and Nigara 1972) 
Other site-specific carriers in addition to antibodies, have 
been used to target daunorubicin. Varga et a1. (1977) have used 
me1anotropin to target daunorubicin to mouse melanoma cells. They 
found that the conjugate was three times more toxic to melanoma cells 
compared to the free drug, although non-specific cells were unaffected. 
Kaneko (1980) has linked daunorubicin to the hormone thyrotropin and 
demonstrated that the conjugate possesses specific affinity to the 
thyroid cells. Concanavalin A, a lectin with specific affinity for 
tumour cells, has been evaluated as a site-specific carrier of 
daunorubicin. The conjugate cured mice bearing Ehrlich ascites 
tumour, but daunorubicin given alone had little effect (Kitao and 
Hattori, 1977). 
1.S.2(c) Drug-macromolecule linkages 
The link between carrier molecule and drug may be either covalent, 
or non-covalent, but most studies have been performed using a covalent 
type of conjugation. While the distribution of the drug is dictated 
by the characteristics of the carrier molecule, the type of linkage 
used has a fundamental effect on the physical and chemical properties 
of the conjugate and, hence, is of great importance in their design of 
drug carrier preparation. 
In considering a suitable linking reaction, the drug and carrier 
functional group moieties available for reaction must be identified. 
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Linking agents which react with functionally important groups with 
respect to pharmacological activity on the drug or carrier molecule, 
may produce inactivation (Ghose and Blair, 1978). Drugs or carriers 
which lack suitable reactive groups may be modified to provide these 
groups. Steroids containing hydroxyl groups have been reacted with 
succinic anhydride to yield a hemisuccinate which is amenable to 
coupling by the carbodiimide method (Abraham and Grover, 1977). 
In the periodate oxidation method, vicinal-hydroxyl groups are 
oxidatively cleaved to yield aldehyde groups which can be used to 
form a Schiff's base linkage (Erlanger, 1973). The conditions under 
which the binding reaction occurs must be carefully considered, as the 
conditions required for some reactions may degrade the drug or carrier. 
Some reagents such as hexamethylene diisocyanate are insoluble in 
water, and require the use of non-aqueous solvent systems which would 
denature a protein carrier. Reagents such as cyanogen bromide and 
the alkyldiimido esters require strongly alkaline cond~tions 
(Poznansky and Cleland, 1980). The carbodimides and glutaraldehydes 
are the most extensively used cross-linking reagents and have been 
used to link a wide range of antitumour drugs to macromolecules 
(Hurwitz et al., 1975; Goodfriend et al., 1964) as well as linking 
haptens to proteins 1n order to elicit antibodies (Erlanger, 1973). 
These reagents have appreciable advantages over comparative cross-
linking schemes. The reactions may be carried out in aqueous solution 
at neutral pH and at room temperature. They also utilise the abundant 
anions and carboxyl groups of protein. However, they may also cause 
protein cross-linking which gives denaturation and inactivation of 
the protein carrier (Erlanger, 1973). 
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Other cross-linking reagents have serious shortcomings which has 
precluded their widespread use. The cyanogen bromide, bisdiazobenzidine, 
and mixed anhydride methods (see Table 1.2) require the use of very 
toxic compounds, while other reagents, most notably diazo linkages and 
cyanogen bromide, react with groups that are of low abundance in 
protein carriers. 
1.5.3 Encapsulation carr1ers 
Encapsulation carriers are those in which the drug is physically 
separated from the surrounding environment. Carriers of this type, 
which have been utilised in chemotherapy, have included ghost 
erythrocytes (Lynch et al., 1980), polyalkylcyanoacrylate nanoparticles 
(Couvreur et al., 1982), albumin micro spheres (Widder et al., 1981) 
and liposomes. Most research into the role of encapsulation carriers 
in chemotherapy has been using liposomes. This is because they are 
very versatile and their physical properties, such as drug loading, 
size, charge and composition, can easily be varied. Liposomal 
entrapment can change the pharmacokinetic properties and toxicity of 
the encapsulated drug. Juliano and Stamp (1978) have shown the 
liposomal encapsulation of daunorubicin increased the plasma half-life 
from five minutes to 150 minutes, and Rahman et al. (1982) demonstrated 
that liposomally encapsulated doxorubicin was only half as cardiotoxic 
as the free drug. Enhanced antitumour activity of liposomally 
entrapped doxorubicin in Ehrlich solid tumour-bearing mice has been 
demonstrated by Shinozawa et al. (1981) who showed that liposomal 
encapsulated doxorubicin inhibited tumour growth by 55% compared with 
free doxorubicin. 
One obstacle to the widespread use of liposomally entrapped drugs 
is that they lack tissue specificity and are rapidly endocytosed by 
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by the reticuloendothelial cells of the liver and spleen. Research is 
in progress to covalently attach antibodies to liposomes (Gregoriadis 
et al., 1982) which would enable them to be targeted to specific tissues. 
The enhanced uptake of liposomes by the reticuloendothelial 
system has been exploited in the treatment of the parasitic diseases 
leishmaniasis and malaria which reside in the liver and spleen (Alving, 
1982). This use of liposomes is discussed in section 1.5.4. 
1.5.4 Macromolecules as carriers of antiparasitic drugs 
The important parasitic diseases leishmaniasis, malaria and chagas 
disease possess an intracellular stage in their 1ifecycle, which is 
difficult to treat by conventional drug therapy. This is thought to 
be due to the inability of drugs to reach the intracellular site of 
the parasite in cytotoxic concentration. Carriers have been successfully 
used in several cases to transport drug to the intracellular parasite. 
The intracellular (amastigote) form of Trypanosoma cruzi 
is refractory to drugs which kill the bloodstream 
(trypomastigote) form. Trouet et a1. (1976) have demonstrated that 
administration of an ethidium bromide-DNA will cure mice infected with 
T. aruzi. Administration of free ethidium bromide increased the 
survival time of the mice tested, but did not affect any cures. However, 
Avila et a1. (1979) confirmed the sensitivity of T. aruzi to ethidium 
bromide, but were not able to cure infected mice by administration of 
an ethidium bromide-DNA complex. 
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Liposomes have been used to target antimonial drugs to the 
intracellular parasite. Leishmania donovani, the causative agent of 
visceral leishmaniasis, resides preferentially in the reticulo-
endothelial cells of the liver and spleen and is therefore vulnerable 
to liposome encapsulated drugs. Alving et a1. (1978) have shown that 
the drug meglumine antimoniate is three hundred times more effective 
when incorporated into liposomes than when given alone. 
Liposomes have also been used to target the antimalarial drug 
primaquine to the tissue schizonts of Plasmodium berghei, which 
invades hepatocytes. An increase in schizonticidal activity, and a 
decrease in toxicity were observed, although the effects were small. 
Liposomes have not been used at present to target drugs to trypanosomes 
of the T. brucei sub-groups, although Greenberg et al. (1979) has 
shown that positively charged fluid liposomes will fuse with the 
trypanosome cell membrane. 
As the examples above have shown, carriers of various types 
possess considerable potential for improving the effectiveness of 
antiparasitic drugs. 
1.6 Aims and objectives of the present investigation 
New drugs are urgently required for the treatment of African 
trypanosomiasis. No new drugs have been brought into field use during 
the past twenty-five years; also, there are serious obstacles to the 
use of some drugs currently available, such as widespread resistance 
to the cattle trypanocides ethidium and antrycide, and the acute 
toxicity of some arsenical drugs such as melarsoprol (Williamson, 1976). 
The lack of new trypanocides has prompted the routine screening of 
. 
known cytotoxic drugs for trypanocidal activity. Williamson and 
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Scott-Finnigan (1978) used a rapid in vitro assay to screen a series 
of antitumour agents for trypanocidal activity. Of the drugs screened, 
daunorubicin was found to possess uniquely high trypanocidal activity, 
permanently abolishing the infectivity of T.b. bruaei at nanomolar 
concentrations and establishing itself as one of the most trypanocidal 
compounds known. However, daunorubicin is totally inactive against 
trypanoSoMes 1n infected mice (Williamson and Scott-Finnigan, 1978). 
This lack of in vivo activity may be considered to be due to either 
(a) daunorubicin not reaching the intracellular target in cytotoxic 
concentrations (pharmacokinetic factors), or (b) metabolic differences 
between the in vivo and in vitro forms of the parasite (metabolic 
factors). 
In either case improved delivery of drug to the organism would 
perhaps circumvent the loss of activity in vivo. Linking of drug to 
a macromolecule would, in the case of daunorubicin, be expected to 
prolong the blood level of the drug since daunorubicin is rapidly 
cleared from the blood (Brown, 1Y83). Hence, increased exposure of 
the organism to the drug would be expected. Similarly, if the 
macromolecule could be endocytosed by the organism, then a greater 
uptake would be expected with a longer residence time in the organism. 
This coupling of daunorubicin to macromolecules was, indeed, 
successful in retaining activity in vivo as explained in the early 
sections of the research and discussion. 
The characteristics of the daunorubicin-macromolecule conjugate 
which were required for activity were then systematically studied by 
(a) variation of the macromolecule, (b) variation of the linkage used 
and (c) measurement of drug release in biological fluids. These 
studies may provide a basis for rationally designed daunorubicin-
macromolecule conjugates with improved properties. 
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The second phase of this study was to establish the mechanism by 
which daunorubicin exerts its trypanocidal effect. The cytotoxicity 
of daunorubicin is believed to be due to intercalation of drug into 
the DNA double helix (Henry, 1976), although other mechanisms such as 
toxicity mediated by reactive oxygen radicals may be important for 
trypanosomes ln view of their lack of enzymic defence towards these 
species (Fairlamb, 1982). Measurement of the ability of a series of 
daunorubicin derivatives to intercalate into DNA, and to stimulate 
lipid peroxidation in biological material, may be compared with their 
trypanocidal activity, and thus may enable the trypanocidal properties 
of daunorubicin to be identified. This may be of use in developing 
drugs in which the trypanocidal properties of daunorubicin can be 
separated from other toxic properties of the anthracyclines. 
The aims of the study were, therefore, (a) to modify daunorubicin 
so as to enhance uptake and overcome pharmacokinetic barriers to 
activity in vivo; (b) to study the metabolism of drug-macromolecule 
conjugate in biological fluids so as to establish the breakdown 
characteristics required for activity, and hence design a drug-
macromolecule conjugate with optimum activity; (c) to investigate the 
trypanocidal mechanism of action of daunorubicin. 
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CHAPTER 2: EXPERIMENTAL METHODS 
2.1 Synthesis of anthracycline cvnjugates 
2.1.1 Materials 
Daunorubicin hydrochloride ('Cerubidin' vials containing 20 mg 
drug plus 100 mg mannitol) was purchased from May and Baker (Dagenham, 
Essex, UK) and used without further purification. Pure daunorubicin 
hydrochloride was purchased from Sigma (Poole, Dorset, UK). 5-Imino-
daunorubicin was a gift from Dr. E.M. Acton (Stamford Research Institute, 
I 
California, USA). 4-Demethoxydaunorubicin, 4-Deoxydaunorubicin, 
I I 1 d bO ° of 3,4-diepidaunorubicin, doxorubicin and 4-deoxy oxoru 1C1n were g1 ts 
from Dr. F. Arcamone (Farmitalia, Italy). 
Bovine serum albumin, histone F1 horse spleen apoferritin and 
dextran were all purchased from Sigma (Poole, Dorset, UK) and horse 
spleen ferritin was purchased from Boehringer Mannheim (Lewes, Sussex, 
UK). Aqueous glutaraldehyde (25%) was purchased from British drug 
Houses (Poole, Dorset, UK), 1-Cyclohexyl-3-(2-morpholinyl-(4)-ethyl)-
carbodiimide metho-p-toluenesulphonate (C.M.D.T.) was purchased from 
Aldrich (Gillingham, Dorset, UK). All other materials were reagent 
grade or analytical grade where appropriate, and were used as purchased. 
Phosphate buffered saline (P.B.S.) was prepared as described in 
Appendix I. Glassware was silanised with dichlorodimethylsilane 
(Hopkins and Williams, London, UK), rinsed in methanol and distilled 
water, and dried before use. Infrared spectra were recorded on a 
Perkin Elmer model 198 spectrometer. Mass spectra were recorded on a 
V.G. Micromass model 16F mass spectrometer, using electron impact 
(70 eV) to ionise the sample. Nuclear magnetic resonance spectra were 
recorded on a 60 MHz Perkin-EImer-Hitachi model R-600 spectrometer. 
Ultraviolet and visible spectra were recorded on a Perkin-Elmer model 
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552S spectrophotometer. Solutions of drug were kept in the dark 
whenever possible. 
2.1.2 Periodate Oxidation ~1ethod 
2.1.2a Daunorubicin-bovine serum albuMin coniuo:ate 
This was prepared essentially as described by Hurwitz et al. (1975) 
as follows. Daunorubicin hydrochloride (20 mg, i.e. 120 mg Cerubidin) 
was dissolved in P.B.S. pH 1.4 (1.0 ml), and sodium periodate solution 
(0.6 ml, O.lM) was added. The mixture was placed in the dark for one 
hour with occasional agitation, then glycerol solution (0.1 ml, 1.0M) 
was added to reduce excess periodate. Bovine serum albumin (30 mg) 
in potassium carbonate buffer (1.0 ml, 0.15M, pH 9.5) was added and 
the reaction mixture stored in darkness for two hours. The reaction 
mixture was then layered onto a Sephadex GSa (coarse grade) column 
(l.S x 30 cm), and eluted with distilled water. Visual observation 
was used to follow the progress of the conjugate fraction through the 
column. The red fraction which eluted at the void volume of the 
column (15 ml as judged by prior elution of dextran blue 2000 
polysaccharide) was collected and freeze dried. 
This gel chromatographic isolation procedure was used for all of 
the conjugates described below, except where an alternative procedure 
is described. The daunorubicin content was derived from the absorbance 
of an aqueous solution of conjugate at the drug 
using a molar extinction coefficient of 11065 cm-
1 
Q)O%),daunorubicin content = 23.3 ~g/mg. 
2.1.?h Daunorubicin dextran conjugate 
Amax of 495 nm, 
Yield = 15.2 mg 
Dextran (200 mg, M.W 10,000) was dissolved in sodium periodate 
solution (10 ml, 0.06M) and kept overnight at room temperature. The 
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solution was dialysed through a semi-permeable membrane (Spectrapor 1) 
for 12 hours against distilled water (lL), and then freeze-dried. 
Daunorubicin hydrochloride (20 mg, i.e. 120 mg Cerubidin) was added 
to a solution of the freeze-dried material (23 mg) in P.B.S. pH 1.4 
1 ml), and stored in darkness overnight at room temperature. Aqueous 
freshly prepared sodium borohydride solution (81 rnM) was added, and 
the mixture was placed in a covered water bath for two hours at 37°C. 
The conjugate was isolated as described in section 2.1.2(a) and the 
amount of daunorubicin present was measured as described ln section 
2.1.8(a). Yield = 16.5 mg (51%), Daunorubicin content = 157 ~g/mg. 
2.1.3 Daunorubicin-bovine serum albumin conjugate (conjugated with 
succinic anhydride) 
Succinic anhydride (200 mg) was added to a solution of bovine 
serum albumin (500 mg) in P.B.S. pH 1.4 (5 ml), and dissolved by gentle 
swirling. The pH of the solution was monitored using a pH meter and 
maintained in the range pH 7-8 by gradual addition of sodium hydroxide 
solution (2M). The solution was kept dark for two hours at room 
temperature, then dialysed overnight through a semi-permeable membrane 
(Visking tubing), against P.B.S. pH 7.4 (approximately 500 ml). 
On the following day the solution was dialysed for four hours against 
distilled water and then freeze-dried. 
Daunorubicin hydrochloride (10 mg, i.e. 60 mg Cerubidin) and 
1-cyclohexyl-3(2-morpholinyl-(4)-ethyl)carbodiimide metho-p-toluene 
sulphonate (400 mg) was added to an aqueous solution of the freeze-
dried material (350 mg in 7 ml), and the mixture was stored in the 
dark overnight at room temperature. The conjugate was isolated as 
described in section 2.1.8(a) and the daunorubicin content was measured 
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as described in section 2.1.8(a). Yield 49.2 mg (49.6%) 
Daunorubicin content = 32.77 pg/mg. 
2.1.4 Synthesis of macromolecular conjugate linked via the 
daunorubicin C-13 carbonyl moiety. 
2.1.4(a) Daunorubicin-bovine serum albumin conjugate (conjugated 
with 4-hydrazinobenzoic acid) 
Bovine serum albumin (1 g) was dissolved in P. B. S. pH 7.4 (10 ml). 
N-Trifluoroacetyl-hydrazinobenzoic acid (250 mg. synthesized according 
to method 2.1.9(a» in dioxan (1 ml) and 1-cyclohexyl-3-(2-morpholinyl-
(4)-ethylcarbodiimide metho-p-toluenesulphonate (400 mg) were added. 
The solution was kept dark for three hours and then adjusted to pH 10.5 
with aqueous triethylamine (O.2M). The solution was heated at 60°C 
for 15 minutes to remove the trifluoroacetyl group. then cooled to 
room temperature and finally dialysed overnight against O.lM phosphate 
buffer pH 7.4. then against distilled water for four hours before 
freeze-drying. Daunorubicin hydrochloride (5 mg. i.e. 30 mg Cerubidin) 
in P.B.S. pH 7.4 (1.0 ml) was added to a solution of the freeze-dried 
product (100 mg) in P.B.S. pH 7.4 (2 ml). and kept overnight in the 
dark at room temperature. The conjugate was isolated by the method 
described in section 2.1.2 and the daunorubicin content was determined 
from the absorbance at the drug A ,of a solution of the conjugate 
max 
(see section 2.1.8(a). yield = 49.2 mg (47.6%) Daunorubicin content 
= 32.77 )Jg/mg). 
2.1.4(b) Daunorubicin-bovine serum albumin conjugate (conjugated 
with amino(oxy)acetic acid) 
Bovine serum albumin (600 mg) was dissolved in P.B.S. pH 7.4 
(10 ml). N-trifluoroacetyl-amino(oxy)acetic acid (150 mg, synthesized 
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according to method 2.1.9(b), and 1-cyclohexyl-3-(2-morpholinyl-(4)-
ethyl)carbodiimide metho-p-toluene sulphonate (350 mg) was added. 
The solution was kept in the dark overnight and then adjusted to 
pH 10.5 with aqueous triethylamine (0.2M). The solution was heated at 
60°C for fifteen minutes to remove the trifluoroacetyl group. then 
cooled to room temperature and, finally, dialysed overnight against 
O.lM phosphate buffer pH 7.4, then against distilled water for four 
hours before freeze-drying. Daunorubicin hydrochloride (5 mg) in 
P.B.S. pH 7.4 (1 ml) was added to a solution of the freeze-dried 
produc t (100 mg) in P.B.S. pH 7.4 (2 ml) and kept overnight in the 
dark at room temperature. The conjugate was isolated by size exclusion 
chromatography as described in section 2.1.2 and the daunorubicin 
concentration was found from the absorbance of a solution of conjugate 
at the drug A (see section 2.1.3(a). Yield = 75.22 (75.6%) 
max 
Daunorubicin content = 25 ~g/mgJ 
2.1.5 Attempted synthesis of daunorubicin-dextran conjugate 
(conjugated with glyoxylic acid). 
1,3-Diaminopropyldextran (150 mg, synthesized according to method 
2.1.9(d), sodium 2-methoxy-2-hydroxyacetate (synthesized according to 
method 2.1.9(c) and l-cyclohexyl-3-(2-morpholinyl-(4)-ethyl) 
carbodiimide metho-p-toluene sulphonate (130 mg). were dissolved in 
P.B.S. pH 7.4 (1 ml). The solution was kept at room temperature for 
six hours. Hydrochloric acid (2M) was added until the acidity of 
the solution reached pH 2-3, and heated under reflux for thirty minutes. 
After cooling, the solution was neutralised with sodium hydroxide 
solution (2M), dialysed against distilled water overnight, and then 
freeze-dried. Daunorubicin hydrochloride (1.5 mg, i.e. 9 mg Cerubidin) 
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1n water (0.3 ml) was added to a solution of the freeze-dried product 
(90 mg in 1 ml P.B.S. pH 7.4) and the solution was placed in the dark 
for six hours at room temperature. Isolation of the product was 
attempted using gel column chromatography as described in section 
2.1.8(a). However, no daunorubicin was eluted in the void volume of 
the column (lS ml as measured using dextran-blue polysaccharide). 
2.1.6 Synthesis of anthracycline conjugates coupled with glutaraldehyde 
2.1.6(a) Daunorubicin-bovine serum albumin conju~ate 
Daunorubicin hydrochloride (8 mg, i.e. 48 mg Cerubidin) and 
glutaraldehyde solution (0.8 ml, 0.4%) were added to a solution of 
bovine serum albumin (400 mg) in P.B.S. pH 7.4 (4 ml). The solution was 
stored in the dark for two hours with occasional agitation and the 
product was then isolated by gel column chromatography as described 
in section 2.1.2. The daunorubicin content was found from the absorbance 
at the drug A of a solution of the conjugate (see section 2.1.8(a). 
max 
yield = 235 mg (57%) Daunorubicin concentration = 19.5fg/mg. 
Studies subsequently performed to determine the extent of 
daunorubicin release from this conjugate revealed the presence of more 
than one bond type (see section 1.3.2). The product was passed through 
a column of porapak Q resin, which absorbed any free drug present. 
The product from this step was designated fraction I. Incubation of 
fraction I in P.B.S. pH 7.4 was accompanied by a further release of 
bound drug, which was also removed by passage through a porapak Q 
column. The product from this step was designated fraction II. 
2.1.6(b) Daunorubicin-bovine serum albumin conjugate (Fraction I) 
Daunorubicin-bovine serum albumin conjugate (167mg) prepared as 
described in section 2.1.6(a) and isolated by geJ column chromatography, 
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was layered onto a Porapak Q column (0.5 x Scm) eluted with 
distilled water. A red fraction that eluted was collected and freeze-
dried. The amount of daunorubicin present in the product was measured 
by visible absorbance and fluorescence methods as described in sections 
2.1.8(a) and 2.1.8(b). 
Yield = 81 mg (48.3%) Daunorubicin content = 3.6 pg/mg. 
2.1.6(c) Daunorubicin-bovine serum albumin conjugate (Fraction II) 
A solution of daunorubicin-bovine serum albumin conjugate 
(containing 600 mg bovine serum albumin and synthesised according to 
method 2.1.6(a»in P.B.S. pH 7.4 (4 ml) was isolated by gel chromatography 
as described in section 2.1.2. One half of the solution (approximately) 
was kept dark overnight at room temperature, then layered onto a 
?orapak Q column (0.5 x 5 cm), eluted with water and freeze dried. 
Yield 303 mg (100%) Daunorubicin content = 3.13 pg/mg. 
2.1.6(d) Daunorubicin-horse spleen ferritin conjugate 
Daunorubicin hydrochloride (2.5 mg, i.e. 15 mg Cerubidin) in P.B.S. 
pH 7.4 (0.5 ml) was added to ferritin (30 mg) and glutaraldehyde 
solution (0.2 ml, 0.4%). The mixture was kept dark for fifteen minutes 
at room temperature. The conjugate was isolated as described in 
section 2.1.2(a). The daunorubicin concentration was found from the 
absorbance of a solution of the conjugate at drug A after max 
reduction of the ferritin iron core (see section 2.1.S(c». 
Yield - 11.1 mg (35%) Daunorubicin concentration = 61 ~g/mg. 
2.1.6(e) Daunorubicin-horse spleen apoferritin conjugate 
Daunorubicin hydrochloride (8 mg, i.e. 48 mg Cerubidin) and 
glutaraldehyde solution (0.4 ml, 0.4%) were added to a solution of 
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horse spleen apoferritin (50 mg) in water (3 ml). The solution was 
placed in a covered water bath for one hour at 37°C with occasional 
agitation. The conjugate was isolated as described in section 2.1.2(a) 
and the daunorubicin content was measured as described in section 2.1.8 (a). 
yield = 20 mg (39%) Daunorubicin content = 20.5 ~g/mg. 
2.1.6(f) Daunorubicin-histone Fl conjugate 
Daunorubicin hydrochloride (1.5 mg, i.e. 9 mg Cerubidin) in P.B.S. 
pH 1.4 and glutaraldehyde solution (0.2 ml, 0.4%) were added to a 
solution of histone F1 (25 mg) in P.B.S. (1 mI). The solution was 
stored in the dark for fifteen minutes at room temperature with 
occasional agitation. The conjugate was isolated as described in 
section 2.1.2(a) and the daunorubicin content was measured by the 
method described in section 2.1.8(a). 
Yield = 18.8 mg (74%) Daunorubicin content = 19 ~g/mg • 
2.1.6(g) Daunorubicin-1,3-diaminopropyldextran conjugate (conjugated 
with glutaraldehyde) 
Daunorubicin hydrochloride (3 mg, i.e. 18 mg Cerubidin) and 
glutaraldehyde solution (0.8 ml, 0.4%) were added to 1,3-diaminopropyl-
dextran (100 mg synthesized according to method 2.1.9(d»in P.B.S. 
pH 7.4. The solution was stored in the dark for fifteen minutes at 
room temperature with occasional agitation, and was then isolated 
as described in section 2.1.2(a). The daunorubicin content was 
measured by the method described in section 2.1.8(a). 
Yield = 64.7 mg (64%) Daunorubicin content = 8.0 ~g/mg. 
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2.1.6(h) 5-Iminodaunorubicin-bovine serum albumin conjugate 
5-Iminodaunorubicin (6 mg) and glutaraldehyde solution (0.4 ml, 
0.4%) were added to a solution of bovine serum albumin (200 mg) in 
P.B.S. pH 7.4 (4 ml). The mixture was stored in the dark for one 
hour at room temperature with occasional agitation. The conjugate 
was isolated as described in section 2.1.2(a) and the drug content 
was measured as described by method 2.1.8(a). 
Yield = 112 mg (54%) Drug content = 28.8 ~g/mg. 
2.1.6(j) Doxorubicin-bovine serum albumin conjugate and 4-demethoxy-
daunorubicin-bovine serum albumin conjugate 
Doxorubicin hydrochloride (6 mg), and glutaraldehyde solution 
(0.3 ml, 0.4%), were added to a solution of bovine serum albumin (160 mg) 
in P.B.S. pH 7.4 (6.6 ml). The solution was stored in the dark for one 
hour at room temperature with occasional agitation. The conjugate was 
isolated as described in section 2.1.2(a), and the drug content was 
measured as described in section 2.1.8(a). This method was also used 
to prepare 4-demethoxydaunorubicin-bovine serum albumin conjugate. 
Yield = 92 mg (57%) Drug content = B.95 ~g/mg. 
2.1.6(k) Various anthracycline-bovine serum albumin conjugates 
This method described in section 2.1.6(i) was used for the 
synthesis of all anthracycline-bovine serum albumin conjugates listed 
in Table 3.7. 
2.1.6(1) Glutarated bovine serum albumin 
Glutaraldehyde solution (0.4%, 1 ml) was added to a solution of 
bovine serum albumin (lg) in P.B.S. pH 7.0 (5 ml). The solution 
was stored in the dark for fifteen minutes at room temperature, and 
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the product was isolated as described in section 2.1.2(a). 
Yield = 609.6 mg (61%). 
2.1.7 Daunorubicin-horse spleen ferritin core complex 
Daunorubicin hydrochloride (2.5 mg, ~.e. 15 mg Cerubidin) ferrous 
sulphate (6 mg), sodium thiosulphate (90 mg), potassium iodate (27 mg) 
and apoferritin (15 mg in 0.6 ml water) were dissolved in phosphate 
buffer pH 7.4 (2 ml). The solution was incubated in the dark at room 
temperature for 15 minutes with occasional agitation. The conjugate 
was isolated as described in section 2.1.2(a). The daunorubicin 
content was measured as described in section 2.1.8(c). 
Yield = 10.7 mg (62.5%) Daunorubicin content = 121.5 ~g/mg. 
2.1.8 Determination of the drug content of anthracycline conjugates 
2.1.8(a) Spectrophotometric determination 
Anthracycline conjugate (approximately 5 mg) was accurately weighed 
on a Gallenkamp analytical microbalance and placed in a glass vial. 
The sample was dissolved in water (2 ml) and the absorbance of the 
solution was measured at the drug A using a dual beam spectrophotometer max 
(Perkin-Elmer 5525), and water as reference. The drug concentration was 
calculated from the appropriate extinction coefficient given below. 
Extinction 
Drug max coefficient Reference 
(M- 1 cm- 1) 
Daunorubicin 495 11065 Bernard et al., 1969 
*Doxorubicin 495 12121 Arcamone et al., 1969b 
4-Demethoxydaunorubicin 485 9200 Zunino et al., 1976 
5-Iminodaunorubicin 592 19800 Tong et al., 1979 
* Measured in methanol 
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I I 
4-Deoxydaunorubicin, 4-deoxydaunorubicin, and 3,4-diepidaunorubicin 
were measured using the appropriate extinction coefficients for 
daunorubicin and doxorubicin. 
2.1.8(b) Spectrofluorimetric determination 
(i) Preparation of the calibration curve 
Daunorubicin (0.5 ml, 24 ~g/ml) in P.B.S. pH 7.4, was placed 
in a centrifuge tube and made up to 1.0 ml with P.B.S. pH 7.4. 
Sulphuric acid (2M, 1.0 ml) was added, and the assay continued as 
described below. The procedure was repeated with five different 
concentrations of daunorubicin. A calibration curve of drug 
fluorescence against concentration was prepared. 
(ii) Assay for daunorubicin 
Daunorubicin-bovine serum albumin conjugate (2 mg) was accurately 
weighed on a Gallenkamp analytical microbalance and placed in a 
clean centrifuge tube. Sulphuric acid (1.0M, 2.0 ml) was added, 
and the conjugate was dissolved with gentle swirling. The tube 
was placed in a heating block at 80 De for ten minutes, then 
cooled to room temperature. Dichloromethane (2 ml, Fisons AnalaR 
grade) was added and the contents were thoroughly mixed using a 
vortex mixer. The tube was sealed and centrifuged at 100 x g for 
five minutes. The aqueous layer was removed with a Pasteur 
pipette and discarded. A portion of the dichloromethane layer 
(0.1 ml) was removed using a precision glass syringe, and placed 
in a silanised test tube. The tube was placed in a heating block 
for two minutes to evaporate the solvent. Aqueous ethanol (50%, 
4 ml) was added and the mixture agitated using a vortex mixer to 
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ensure all the drug residues were dissolved. The fluorescence 
of the solution was measured in a Perkin-Elmer model 2000 
spectrofluorimeter (excitation = 471 nm, emission = 557 nm). The 
concentration of daunorubicin in the original sample was found 
by reference to the calibration curve. 
2.1.8(c) Measurement of drug content in ferritin conjugate 
Daunorubicin-ferritin conjugate (approximately 2 mg) was accurately 
weighed on a microanalytical balance, and placed in a clean glass vial. 
Water (1 ml) was added and the conjugate was dissolved with gentle 
swirling. 2-Thioacetic acid (1%, 1 ml) in sodium acetate buffer (0. 15M, 
pH 4.6) was added. After ten minutes the absorbance of the solution 
was measured at 495 nm in a dual beam spectrophotometer (Perkin-Elmer 
model 552S) against a water blank. The concentration of daunorubicin 
, ,. ff' , -1 -1 was calculated assum1ng an ext1nct1on coe 1C1ent of 11065 M cm 
(Bernard et al., 1969). 
2.1.9 Synthesis of linking agents for conjugate preparation 
2.1.9(a) N-Trifluoroacetyl hydrazinobenzoic acid 
4-Hydrazinobenzoic acid (5g, technical grade) and methanol (500 ml) 
were placed in an Erlenmeyer flask (lL) and gently heated with stirring 
until most of the hydrazinobenzoic acid was dissolved. The solution 
was filtered rapidly into a clean Buchner flask (lL). Water (300 ml) 
was added and a precipitate of hydrazinobenzoic acid formed. The 
precipitate was removed by filtration under vacuum and washed with 
small aliquots of methanol and dried at 40°C overnight in vaouo. 
A portion of this hydrazinobenzoic acid (3g) was placed in a 
round-bottomed flask (50 ml) and trifluoroacetic anhydride (10 ml) was 
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carefully added. The flask was stoppered and kept dark for two days, 
after which ti~e hydrazinobenzoic acid had completely dissolved. Water 
(20 ml) was added dropwise, and a white product formed. The product 
was filtered, washed with water and dried at 40°C for two hours in vacuo. 
Crude product (500 mg) and methanol (10 ml) were placed in a 
centrifuge tube and gently heated to dissolve the product. Water (5 ml), 
was added and the solution was centrifuged for 5 minutes at 1000x g. 
The aqueous layer and the top layer of brown solid material were 
discarded. Methanol (10 ml) was again added and the procedure was 
repeated. The purified product was dried at 40°C for two hours in vacuo. 
Yield = 4.8g (76%) m.p. 320-340°C (decomposed). 
Elemental analysis C,44.75; H,2.76; N,11.71%. C9H703N2F3 requires 
C,43.56; H,2.84; ~ 11.29%. 
loR. (Nujol mull) 3500, 3200, 1775, 1670, 1605, 1240, 1165, 1145, 1015, 
-1 
940, 890, 720 cm • 
H1 P.M.R. (0 from T.M.S. in CDCl3) 7.84 (2H,m), 8.36 (2H,m), 
9.100 (lH,S)*, 14.8 (2H,S)* 
* Exchangeable with D20. 
Mass spectrum mle (5) 207 (1.5), 197 (2),181 (1.5),90 (20), 83 (10) 
74 (15), 64 (40),59 (35),45 (100). 
2.1.9(b) N-Trifluoroacetyl-amino(oxy)acetic acid 
Amino(oxy)acetic acid hemihydrochloride (lg, 13.9 mmol) was placed 
in a round-bottomed flask, and trifluoracetic anhydride (3 ml, 21 mmol) 
was carefully added. The solution was kept for 24 hours at room 
temperature. Unreacted trifluoracetic anhydride was removed by 
evaporation under vacuum at 40°C, to yield an oil. Ether (20 ml) was 
added, and the white crystalline precipitate was removed by filtration 
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washed with ether and dried under vacuum. 
Yield = 886 mg (51%) m.p. = 102-104°C. 
LR. (Nujol mull) 2700, 1780, 1610, 1500, 1480, 1050, 888, 845, 
-1 
795, 690 em • 
Mass spectrum mle (%) 143 (10), 127 (9), 115 (20), 104 (5), 92 (55), 
86 (10), 69 (75), 46 (100). 
2.1.9(c) Sodium 2-methoxy-2-hydroxy acetate 
Methanol (200 ml), dried by the method of Lund and Bjerrum (1931) 
was placed in a dry round-bottomed flask (21) fitted with a reflux 
condenser. Sodium (16g, 0.7M) was added and dissolved without 
additional warming. 
Dichloroacetic acid (16 ml, 0.14M, redistilled) was added dropwise 
over 15 minutes while the solution continued to boil. The solution 
was heated over a steam bath for three hours at 90°C, then cooled to 
room temperature. The solution was neutralised by addition of methanolic 
hydrochloric acid (6M) and monitored with a pH meter until an acidic 
pH was reached •. Methanol was removed by evaporation under vacuum and 
the product was recrystallised from methanol/chloroform (1:5 V/V). 
Yield = 20g (83%) m.p. = 184°C (decomposed). 
Elemental analysis: C, 28.25; H, 3.71%. C3H504N requires C, 28.11; 
H, 3.93%. 
I.R. (Nujol mull) 3450, 1680, 1320, 1200, 1115, 1055,946,917,810, 
-1 
787, 746 cm • 
H1 N.M.R. (6 from T.M.S. in D
2
0) 4.75 (3H,S), 6.15 (1H,S). 
Mass spectrum ro/e (%) 123 (1), 111 (4), 97 (12), 89 (15), 83 (18), 
75 (100), 69 (25), 57 (30). 
2.1.9(d) Hvdrolysis of sodium 2-methoxy-2-hydroxy acetate 
Sodium 2-methoxy-2-hydroxy acetate (300 mg) was dissolved in water 
(5 ml) and acidified to pH 2 by addition of dilute hydrochloric acid. 
The solution was heated at 50°C for two hours. Water was removed by 
evaporation under vacuum. The infrared spectrum of the residue was 
recorded and compared with the starting material, and a sample of 
glyoxylic acid (section 3.1). 
I.R. (Nujol Mull) 3400, 1730, 1625, 1305, 1260, 1200, 1120, 1070, 
-1 
1000, 722 cm • 
2.1.g(e) 1,3-Diaminopropyl dextran 
Cyanogen bromide (2g, 18 romol) was added to a stirred solution of 
dextran T.40 (2g, Pharmacia Uppsala, Sweden) in water (5 ml). 
Sufficient sodium hydroxide solution (2M) was added to adjust the 
mixture to pH 12.5. The solution was continuously monitored throughout 
the reaction with a pH meter, and maintained in the range pH 11.5-12.5 
by further additio~ of sodium hydroxide solution. 
After ten minutes the pH of the solution was readjusted to pH 8 
by addition of hydrochloric acid (2M). 3-Aminopropanitrile (lg, 14 mM) 
was added and the solution was stirred continuously. After sixteen 
hours the solution was acidified to pH 1 with hydrochloric acid (2M), 
and dialysed extensively against distilled water before freeze-arying. 
The freeze-dried residue was suspended in dry ether (200 ml) and 
lithium aluminium hydride (0.4g, 10.5 mM) was added. The mixture was 
heated under reflux for two hours. Ether was removed by evaporation 
under vacuum, and water (100 ml) was slowly added to decompose unreacted 
lithium aluminium hydride. The aqueous suspension was filtered and 
freeze-dried. Yield = 430 mg. 
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2.2 Synthesis of daunorubicin derivatives 
2.2.1 Materials 
Daunorubicin hydrochloride was purchased as 'Cerubidin' (vials 
containing 20 mg drug plus 100 mg mannitol) from May and Baker Ltd. 
(Dagenham, Essex, England), and used without further purification, or 
as the free base prepared as described in section 2.2.2. Sodium 
stearate and acetic anhydride were also purchased from May and Baker Ltd. 
2.2.2 Preparation of daunorubicin free base 
Cerubidin (240 mg containing 40 mg daunorubicin hydrochloride) 
was dissolved in sodium bicarbonate solution (10 ml, 5%) and extracted 
with chloroform (3.20 ml). The chloroform extracts were pooled, dried 
with sodium sulphate, filtered and evaporated to dryness under reduced 
pressure. The product was dried in a vacuum dessicator over phosphorus 
pentoxide for seven days. 
2.2.3 Synthesis of N-3_cetyldaunorubicin 
Daunorubicin free base (from 40 mg of hydrochloride salt) was 
dissolved in dry acetone (10 ml). Acetic anhydride (0.5 ml) was added 
and the solution was stirred for two hours. Acetone was removed by 
evaporation under vacuum, and the residue was freeze-dried to remove 
excess acetic anhydride. The crude product was purified by preparative 
thin layer chromatography (T.L.C.) on Kieselgel 060 plates (1 rom 
thickness), using chloroform:methanol:acetic acid (90:9:1) as the 
mobile phase. A red band (Rf = 0.6) was removed, extracted with 
methanol and the extract evaporated to dryness under reduced pressure. 
The residue was purified by high pressure liquid chromatography 
(H.P.L.C.) using a Lichrosorb RP2 column (0.5-30 cm), and acetonitrile: 
water (3.5:1.5) as the mobile phase. The mobile phase was eluted at 
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a rate of 2.0 ml/minute and monitored at 480 nm by a spectrophotometer 
(Cecil model 273), fitted with a 30 ~l flow cell. The residue was 
dissolved in methanol (2 ml) and injected onto the H.P.L.C. column in 
aliquots of 0.5 mI. The eluate fraction containing the major product 
was collected in a clean, dry, round-bottomed flask, and freeze-dried. 
Yield = 19 mg (45%) m.p. = 172°C (Lit m.p. 166-177, Yamamotoetal 1972). 
H1N.M.R. (6 from T.M.S. in CDCI 3) 1.28 (3H,d), 1.85 (2H,m), 1.95 (3H,S), 
2.08 (lH,m), 2.3 (lH,m), 2.4 (3H,S), 2.9 (lH,d), 3.2 (lH,d), 3.5 (3H,S), 
3.7 (lH,S), 4.0 (3H,S), 4.2 (3H,m), 5.2 (lH,S), 5.5 (lH,S), 5.9 (lH,d), 
7.3 (lH,d), 7.8 (lH,t), 8.0 (lH,d). 
Mass spectrum m/e (%) 172 (10), 154 (2), 153 (10), 144 (10), 138 (30), 
125 (20),114 (40),102 (20), 96 (25), 84 (40), 72 (100). 
2.2.4 Synthesis of doxorubicin-14-stearate 
Daunorubicin hydrochloride (40 mg, dried over phosphorus pentoxide) 
was dissolved in a mixture of methanol and dioxan (2 ml) and dry 
methanol (6 ml). Bromine solution (0.25 ml containing 0.35 ml Br in 
2 
10 ml chloroform) was added and the mixture was left to stand for 
four hours, then filtered and evaporated to dryness under reduced 
pressure. Acetone (14 ml) and sodium stearate (200 mg) were added 
and the mixture was heated under reflux for one hour, then filtered 
and evaporated to dryness under reduced pressure. 
The crude product was dissolved in methanol (1.5 ml) and 
hydrochloric acid (4.5 ml, O.lM) and extracted several times with 
chloroform. The extracts were combined, dried with sodium sulphate 
and evaporated to dryness. The product was recrystallised from 
chloroform-methanol. 
Yield - 18.3 mg (61%). 
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1 
H N.M.R. (6 from T.M.S.) 0.9 (6H,m), 1.2 (24H,S), 1.7-2.7 (18H,S), 
2.9-3.2 (2H,m), 3.5 (4H,m), 4.1 (5H,m), 4.4 (lH,S), 5.2 (lH,S), 
6.6 (2H,S), 7.0 1H,S), 7.5 (lH,d), 7.8 (lH,t), 8.0 (lH,d), 13.2 (lH,S), 
13.7 (lH,S). 
I.R. (Nujol Mull) 3480, 1737, 1617, 1580, 1287, 1213, 1170, 1140, 
-1 
1070, 1030, 990, 810, 720 cm • 
2.3 Release of drug from daunorubicin-bovine serum albumin conjugate 
1n biological fluids 
2.3.1 Materials 
Dichloromethane (AnalaR grade) was purchased from Fisons 
(Loughborough, Leicestershire, UK). Daunorubicin hydrochloride was a 
gift from Dr. F. Arcamone (Farmitalia, Milan, Italy). The monomorphic 
Liverpool strain of Trypanosoma rhodesiense (Yorke et al., 1929) was 
used throughout this investigation. Isolation of trypanosomes from 
infected mice, which is described in section 2.3.3, was carried out 
by Mr. T.J. Scott-Finigan (N.I.M.R., Mill Hill, London). Preparation 
of P.B.S. pH 7.4 citrate saline and Krebs glucose solution are 
described in Appendix I. 
2.3.2 Animals 
Murine plasma was prepared from male Swiss mice (25-30g) fed on 
diet 41B (Pilsbury's, Birmingham). Trypanosomes were isolated from 
infected Parkes mice fed on diet 41B. 
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2.3.3 Preparation of biological fluids 
2.3.3(a) Murine plasma 
Swiss mice (25-30g) were killed by cervical dislocation. Blood 
(0.5 ml) was removed from each mouse by cardiac puncture and placed in 
a heparinised centrifuge tube. The tube was centrifuged at 1000 x g 
for three minutes. The plasma layer was removed with a Pasteur 
pipette and transferred to a glass vial. 
2.3.3(b) Trypanosome homogenate 
Mice were infectedwithTPypanosoma rhodesiense (see section 2.3.1 and 
2.6.3) and the parasitaemia was allowed to proceed until the infection 
06 07 . -1 exceeded 1 - 1 paras1tes, ml . Blood from ether anaesthetised 
mice was removed by cardiac puncture and diluted with citrate saline. 
The blood was centrifuged at 600 x g for ten minutes. The trypanosom-e 
layer was removed, resuspended in Kreb's glucose solution and 
centrifuged at 600xg for five minutes to give a pellet of trypanosomal 
material. Water (1 ml) was added to the trypanosomal pellet (1 ml) 
and the mixture was homogenised in a glass mortar with a teflon pestle 
for five minutes. 
2.3.4 Preparation of calibration curves for daunorubicin in P.B.S. 
pH 7.4 and Murine Plasma 
-1 
Daunorubicin hydrochloride (50 ~l, 10 ~g ml ) in P.B.S. pH 7.4 
was placed in a silanised centrifuge tube. Murine plasma (50 ~l) 
and P.B.S. pH 7.4 (0.9 ml) were added to give a volume of 1.0 mI. 
Sodium bicarbonate solution (100 ~l, 5%) and dichloromethane (1.0 ml) 
were added and the components were thoroughly mixed using a vortex 
mixer. The tube was centrifuged at 1400 x g for five minutes. The 
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aqueous layer was removed and discarded and an aliquot of the dichloro-
methane layer (0.5 ml) was transferred to a silanised test tube and 
heated at 45°C under a nitrogen atmosphere until the solvent had 
evaporated. 
Sulphuric acid (4 ml, O.OlM) was added and the mixture agitated 
uS1ng a vortex mixer to ensure all drug residues were dissolved. The 
fluorescence of the solution was measured in a grating spectro-
fluorimeter (Perkin-Elmer model 2000) using emission and excitation 
wavelengths of 552 and 471 nm respectively. The procedure was repeated 
using differing volumes of daunorubicin solution in the range 0-20 pl. 
The volume of P.B.S. pH 7.4 added was adjusted to give a total volume 
of 1.0 mI. A graph of fluorescence against drug concentration was 
prepared (section 3.2). The procedure was also used to prepare a 
calibration curve of daunorubicin in P.B.S. pH 7.4. For this curve, 
P.B.S. pH 7.4 (0.95 ml) was added and murine plasma was excluded. 
2.3.5 Release of drug from daunorubicin-bovine serum albumin conjugate 
in murine plasma and phosphate buffered saline pH 7.4 
Daunorubicin-bovine serum albumin conjugate (2 mg) was accurately 
weighed on an analytical microbalance (Gallenkamp) and placed in a 
silanised stoppered vial (21 ml). Freshly prepared murine plasma 
(see section 2.3.3(a» was added, and the vial was sealed, covered with 
aluminium foil to exclude light, and placed in a water bath at 37°C. 
Samples (50 pI) were removed at intervals using a precision microlitre 
syringe and each placed in a centrifuge tube containing P.B.S. pH 7.4 
(0.95 ml). Sodium bicarbonate solution (0.1 ml, 5%), and dichloromethane 
(1.0 ml) were added. Each tube was capped, the contents thoroughly 
mixed using a vortex mixer, and then centrifuged at 1000g for five 
minutes to separate the components. The aqueous layer was removed and 
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discarded. Part of the dichloromethane layer (0.5 ml) was transferred 
to a silanised test tube and placed in a heating block at 45°C in a 
nitrogen atmosphere until the solvent had evaporated. Sulphuric acid 
(4 ml, O.OlM) was added with thorough mixing to ensure that all drug 
residues were redissolved. The fluorescence emission was measured 
using a Perkin-Elmer model 2000 spectrofluorimeter (excitation - 471 nm 
emission - 557 nm). 
2.3.f) Release of drug from daunorubicin-bovine serum albumin 
conjugate in trypanosomal homogenate 
The method used was essentially as described in 2.3.5(a), except 
for minor changes which are given below. 
Daunorubicin-bovine serum albumin conjugate (2 mg) was accurately 
weighed on an analytical microbalance and placed in a clean, silanised 
glass vial (2 ml). Trypanosome homogenate (0.3 ml), prepared according 
to method 2.3.3(b), was added and the vial was sealed, covered with 
aluminium foil to exclude light, and placed in a water bath at 37°C. 
Samples (30 ~l) were removed at intervals of time using a 
microlitre syringe and placed in a centrifuge tube containing phosphate 
buffered saline (0.97 ml). 
Preparation and measurement of the sample continued as described 
in method 2.3.5(a). 
2.4 Determination of the affinity of anthracycline drugs for DNA 
2.4.1 Materials 
Nogalamycin and 7-con-0-methylnogarol were gifts from Dr. P.F. Wiley 
(Upjohn Co., Kalamazoo, Michigan, USA). N,N-Dibenzyldaunorubicin was 
a gift from the National Cancer Institute (Bethesda, Maryland, USA). 
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5-Iminodaunorubicin was a gift from was a gift from Dr. E.M. Acton 
(Stamford Research Institute, Palo Alto, California, USA), and 
daunorubicin was a gift from Dr. F. Arcamone (Farmitalia, Milan, Italy). 
N-acetyldaunorubicin was synthesised as described in section 2.2. 
Calf thymus D.N.A. (type I) and agarose (type I) were purchased from 
the Sigma Chemical Co. (Poole, Dorset, England). PM2-DNA was purchased 
from Boehringer Mannheim (Lewes, Sussex, England). Tris buffer A and 
tris buffer B were prepared as described in the Appendix. 
2.4.2 Determination of the denaturation temperature (Tm)of DNA in 
the presence and absence of drug. 
2.4.2(a) Preparation of DNA solution 
Calf thymus DNA (50 mg, Sigma type I) was placed in a small 
beaker. Tris buffer A (pH 7.4, 50 ml) was added. The beaker was covered 
with adhesive film and placed in a refrigerator at 4°C. DNA was 
dissolved by gentle swirling once a day until solid material was no 
longer visible. 
The concentration of DNA was found from the absorbance of a 1:20 
dilution, assuming a molar extinction coefficient of 6600 (Plumbridge 
and Brownm 1978). The concentration of DNA solution prepared by this 
method was approximately 2.5 x 10-3M. Calf thymus DNA solution 
prepared by this method was used throughout this investigation. 
2.4.2(b) Thermal denaturation temperature (Tm) of calf thymus DNA 
Water (6 ml) and tris buffer (3 ml) were placed in a silanised 
volumetric flask (10 ml) and sonicated for fifteen minutes to remove 
dissolved air. DNA solution was added to g1ve a final concentration 
-4 
of 1.5 x 10 M. Tris buffer was added so that the final volume of 
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buffer was exactly 3.6 ml, and the flask was made up to volume with 
distilled water. 
The solution (2.5 ml) was placed in a quartz V.V. cell fitted with 
a ground glass stopper. Teflon tape was wrapped around the stopper to 
provide an airtight seal. The cell was placed in the heating compartment 
of a Perkin-Elmer model 5525 spectrometer fitted with a temperature 
programmer. The spectrophotometer was set at 260 nm, and the 
temperature of the cell was raised from 58 to 100°C at a rate of 
0.5°C/minute. A chart recorder was used to record changes in the 
absorbance of the sample as the temperature was raised. Tris buffer 
(3.6 ml in 10 ml water) was used as the reference solution. 
2.4.2(c) Determination of the thermal denaturation temperature (Tm) 
of calf thymus DNA in the presence of drug 
For samples containing drug the method was the same as that used 
in method 2.4.2(b) except for minor changes which are shown below. 
A solution of drug (1 x 10-~)in water (10 ml) was prepared. 
Tris buffer (3 ml), water (4.5 ml) and drug solution (1.5 ml) were 
placed in a silanised volumetric flask (10 ml) and sonicated for 
fifteen minutes. The volume of drug solution added was adjusted so 
that the final concentration was exactly 1.5 x 10-~. DNA solution was 
•• • 5 10-4 added to g1ve a f1nal concentrat1on of 1. x M when made up to 
10 ml. Tris buffer was added to give a total final volume of 3.6 mI. 
The flask was made up to volume with water and the experiment 
continued as described in section 2.4.2(b). 
2.4.3 Shift in drug absorption spectrum in the presence of DNA 
A solution of drug (1 x 10-4M) was prepared in water and 5.0 ml 
was added to each of five si~anised volumetric flasks (10 ml). DNA 
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solution was added to g1ve a range of DNA/drug ratios 0 to 10, and 
the flasks were made up to volume with tris buffer A (pH 7.4). The 
spectra of the five solutions were recorded over a range 100 nm either 
side of the drug Amax' and superimposed. 
2.4.4 Effect of pH on the drug absorption spectrum 1n the presence 
and absence of DNA 
Two solutions were prepared in a silanised volumetric flask (10 ml), 
the first containing drug (1 x 10-
4
M, 5.0 ml) and the second containing 
-4 -3 drug (1 x 10 M, 5.0 ml) and DNA (2.5 x 10 M, 0.2 ml) in tris buffer A 
(pH 7.4). The solutions were made up to volume with tris buffer A 
(pH 7.4). Two more solutions were prepared containing identical 
amounts of drug and DNA solution, adjusted to pH 9.4 by addition of 
sodium hydroxide solution (2M) and made up to volume with distilled 
water. The spectra of the solutions were recorded over a range 100 nm 
either side of the drug A ,and superimposed. The shift in drug max 
Amax which occurred on basification in the presence and absence 
of DNA was noted. 
2.4.5 Spectrofluorimetric titration of drug with DNA 
Drug solution (2.5x 10-6M, 3.0 ml) in tris buffer A (pH 7.4) was 
added to two fluorimeter cells and placed in a spectrofluorimeter, 
together with a reference cell containing tris buffer A (pH 7.4), 3.0 ml). 
The excitation wavelength was set at the drug Amax and the emission 
wavelength was found by scanning over a range 30-100 nm above the drug 
A ,and the fluorescence emission was recorded. Aliquots of DNA max 
solution (5x 10-
4
M, 20-100 ~l) in tris buffer A (pH 7.4) were added to 
each cell using a precision microlitre syringe. After each addition, 
the solutions were carefully stirred, and stood for five minutes in the 
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dark to allow the DNA/drug complex to reach equilibrium; the fluorescence 
was then recorded. Addition of DNA aliquots continued until no further 
significant change in fluorescence occurred. The DNA/drug ratios and 
fluorescence (corrected for volume change) were calculated. 
2.4.6 Electrophoretic mobility of covalently closed circular PM2-DNA 
1n the presence of drug 
This method was essentially as described by Espejo and Lebowitz 
(1981). PM2-DNA (50 ~g) was dissolved in tris buffer B (pH 7.4, 0.5 ml) 
and allowed to stand for three days at 4°C. Agarose (0.5g) was 
dissolved in tris buffer A (pH 7.4, 50 ml) by heating at 100°C for ten 
minutes, and aliquots of this solution (5 ml) were poured into eight 
test tubes placed in a waterbath at 60°C. An appropriate volume of 
drug solution containing 100 ~g/ml was added using a precision micro-
litre syringe, to give a range of final concentration from 0-0.2 ~g!ml 
(0-0.4 ~g/ml was used for some drugs). The agarose solutions were 
carefully poured into electrophoresis tubes (12.5 x 0.58 cm) which had 
previously been sealed at one end with Nescofilm, and allowed to set 
(two hours). The tubes were kept dark throughout the experiment to 
prevent photodecomposition of drug. The upper end of the gel was 
sliced off and the Nescofibnwas replaced by cotton gauze soaked in 
tris buffer A. 
PM2-DNA solution (20 ~l) was carefully layered onto the surface 
of the gels, followed by a solution of bromophenol blue and sucrose 
(20%, 20 ~l). The gels were then.kept dark for two hours until the 
DNA solution had soaked into the gel surface, and placed in a tube 
electrophoresis cell apparatus. The upper and lower chambers were 
filled with tris buffer A and subjected to electrophoresis at 50V 
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until the bromophenol blue indicator had migrated about half the length 
of the gel (3-4 hours). The gels were extruded and soaked overnight in 
ethidium bromide solution (0.5 ~g/ml). The bands were detected under 
ultraviolet light and either measured or photographed on Ilford 400 ASA 
black and white film using an SLR camera fitted with a short focus 
lens and a red filter. 
2.5 Effect of anthracycline drugs on lipid peroxidation in biological 
systems 
2.5.1 Materials 
Anthracycline drugs were obtained as previously described in 
section 2.4.1. NADPH, NADP, glucose-6-phosphate and glucose-6-phosphate 
dehydrogenase were purchased from Sigma Chemical Company (Poole, 
Dorset, UK). Thiobarbituric acid was purchased from British Drug 
Houses (Poole, Dorset, UK), and 1,1',3,3'-tetramethoxypropane was 
purchased from Aldrich Chemical Company (Gillingham, Dorset, UK). 
Other chemicals were reagent grade and were used as purchased. NADPH 
generating solution, Kreb's glucose and citrate saline solutions were 
prepared as described in tne Appendix. 
2.5.2 Animals 
Swiss male mice (approximately 30g), fed on a normal laboratory 
diet (diet 41B Pilsbury's, Birmingham), were used in the preparation of 
liver microsomes. The animals were starved for eighteen hours prior to 
tissue preparation, but were given drinking water ad Libitum. Parkes 
mice (25-30g), fed on normal laboratory diet 41B, were used for 
experiments involving Trypanosoma rhodesiense. 
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2.5.3 Preparation of mouse liver microsomes 
The animals were killed by cervical dislocation and exsanguinated. 
Each liver was immediately dissected and immersed in a beaker of ice-
cold isotonic P.B.S. pH 7.4. All subsequent operations were carried out 
at 0-4°C. The livers were blotted dry, weighed and homogenised (lg of 
liver with 2 ml of isotonic P.B.S. pH 7.4) using a Potter-Elveljehm 
glass mortar homogeniser with a motor driven teflon pestle. The 
homogenate was centrifuged at 10,000 x g (M.S.E. High Speed 18 
refrigerated centrifuge) for thirty minutes in order to sediment cell 
debris, nuclei, mitochondria and lysosomes. The 10,000xg supernatant 
was carefully decanted and centrifuged at 100,000xg for One hour 
(Beckmann LE65B ultracentrifuge). The supernatant was discarded and 
the microsomal pellet resuspended in P.B.S. pH 7.4 (lg of liver in 
2 ml) using a vortex mixer. 
2.5.4 Preparation of trypanosome suspension 
Parkes mice were infected with Trypanosoma phodesiense by intra-
peritoneal injection and the parasitaemia was allowed to proceed until 
. . d d 6 7 1- 1 Th . the 1nfect1on excee e 10 -10 trypanosomes m • e m1ce were 
killed by cervical dislocation and blood (0.5 ml) was removed by cardiac 
puncture and added to citrate saline (1.0 ml). The citrate/blood 
mixture was centrifuged at 600xg for ten minutes and the trypanosome 
layer was resuspended in Kreb's glucose and centrifuged at 600xg for 
ten minutes. The pellet was resuspended in culture medium consisting 
of Kreb's glucose (90%) and inactivated rat serum (10%). The 
concentration of trypanosome was measured using a haemacytometer and 
diluted with culture medium to the required concentration. 
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2.5.5 Preparation of trypanosomal microsomes 
Pelleted trypanosomes (2 ml, prepared as described in section 2.5.4) 
were homogenised at 30,000 r.p.m. for four minutes, followed by 
40,000 r.p.m. for one minute, 1n a Virtis model 60K tissue homogeniser. 
The homogenate was diluted to 20 ml with sucrose solution (0.25M sucrose, 
1 mM E.D.T.A.) and centrifuged at 1000x g for ten minutes to sediment 
cell debris. The 1000xg supernatant was carefully decanted and 
centrifuged at 105,000xg for one hour, then at 139,000xg for a 
further hour, in a Sorvall 55-34 ultracentrifuge. The 139,000 x g 
supernatant was discarded and the microsomal pellet was resuspended in 
phosphate buffer (O.lM, pH 7.4, 2 ml). 
2.5.6 Determination of tissue protein content 
Microsomal and whole trypanosome protein was assayed by the method 
of Lowry et al. (1951) as modified by Legget-Bailey (1967). 
Trypanosomal microsome protein was determined by the method of Whitaker 
and Granum (1980). 
The Lowry method was as follows: Each tissue preparation (10 ~l) 
was diluted 1 in 10 (1 in 50 for certain preparations) with distilled 
water. Sodium carbonate (1g) was dissolved in sodium hydroxide 
(O.lM, 50 ml) mixed with copper sulphate (1 ml, 0.5%). Sodium citrate 
solution was prepared immediately before use from stock solutions of 
each component (Solution A). An aliquot of solution A (1.0 ml) was 
added to an aliquot (0.1 ml) of each of the tissue dilutions, and the 
mixture was allowed to stand for ten minutes at room temperature. 
Folin-Ciocalteau reagent (0.1 ml, 50%) was added and the solutions 
were thoroughly mixed, then allowed to stand for thirty minutes, after 
which the absorbance was determined at 750 nm. A series of standards 
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containing bovine serum albumin (0-1.0 mg/ml) in distilled water, was 
used to obtain a calibration curve of absorbance against concentration. 
Protein content of the tissue preparations was obtained from this graph. 
2.5.6(b) 
The Whitaker and Granum (1981) method used was as follows: 
Trypanosomal microsomes (100 ~l) were diluted 1 in 20 with dilute sodium 
hydroxide solution. The absorbance was measured at 235 and 280 nm, 
and the protein concentration was calculated using the following formula: 
Protein concentration (mg/ml) = (A235-A280)/2.51 
2.5.7 Microsomal production of malondialdehyde in the presence of 
anthracycline drugs 
Microsomal suspension (0.1 ml), drug solution (0.3 ml, 0.1 mM) in 
0.1M phosphate buffer, and NADPH generating system (0.2 ml) prepared 
as described in the Appendix y were concentrated at 370 C for thirty minutes 
(liver microsomes) or one hour (trypanosomal micr6somes). The incubation 
was terminated byaddition of trichloroacetic acid (50 mM, 0.3 ml in 
50 roM sodium hydroxide). The solution was heated at 90°C for fifteen 
minutes, cooled to room temperature, then centrifuged in a single speed 
haematocrit centrifuge (Hawksley, Sussex, England) to remove suspended 
particles. The absorbance was recorded over the range 580-500 nm and 
the absorbance at 532 nm was noted. The concentration of malondialdehyde 
was calculated using an extinction coefficient for the malondialdehyde-
. 3M-l 1 thiobarbituric aC1d complex of 1.51 x 10 cm- • The result was 
corrected for drug absorbance at 532 nm. 
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2.5.8 Heasurement of malondialdehyde in trypanosome and liver microsomal 
fractions from mice treated with anthracycline drugs in vivo 
2.5.8(a) Preparation of samples 
Parkes mice were infected with Trypanosoma rhodesiense by intra-
peritoneal injection as described in section 2.6.3. After twenty-four 
hours, eight mice were given drug (0.5 ml, 0.6 mg/ml In 70% citrate 
saline/30% murine blood) by intraperitoneal injection. Control mice 
were given 0.5 ml of 70% citrate saline/30% murine blood. Four hours 
later four mice from each group were killed by cervical dislocation. 
The livers were immediately removed and micro somes were prepared from 
the liver tissue as described in section 2.5.3(a). Blood was taken by 
cardiac puncture (0.5 ml/mouse), added to an equal volume of citrate 
saline and centrifuged at 600 x g for ten minutes. The trypanosome 
layer was carefully removed using a Pasteur pipette, and the 
malondialdehyde concentration was measured as described below. 
2.5.8(b) Measurement of malondialdehyde 
Thiobarbituric acid (0.5 ml, 50 mM in 50 mM sodium hydroxide) and 
trichloroacetic acid (1.0 ml, 10%) were added to tissue suspension 
(0.5 ml). The solution was heated at 90°C for fifteen minutes, then 
cooled to room temperature. The solution was centrifuged for two 
minutes in a single speed haemotocrit centrifuge (Hawksley, Sussex, 
England). The absorbance was recorded in the range 500-580 nm and 
the absorbance at 532 nm was noted. 
2.5.9 Measurement of oxygen consumption of trypanosomes in the 
presence of anthracycline drugs 
6 -1 
A trypanosome suspension (4 ml, 1.0xl0 trypanosomes 1 ml , 
prepared according to method 2.5.4) was placed in an oxygen meter 
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(Yellow Springs Instruments model 53) at 37°C, and the oxygen consumption 
was recorded. Aliquotsof drug solution (1.0 mM 1n Kreb's glucose) were 
added to give concentrations of 0.05 and 0.1 mM. After each addition 
the rate of oxygen consumption was recorded. After each experiment the 
suspension was microscopically examined and the mobility of the 
parasite was noted. 
2.5.10 Measurement of oxygen consumption of tissue preparations in the 
presence of anthracycline drugs 
Liver micro somes (0.2 ml), prepared according to method 2.5.3(a» 
or trypanosome homogenate (0.2 ml, prepared according to method 2.3.3(b) 
and NADPH generating solution (0.5 ml prepared as described in the Appendix). 
were placed in an oxygen meter (S.E.A. model OM1) at 37°C, and the 
oxygen consumption was recorded. Aliquots of drug solution (1.0 mM in 
O.lM phosphate buffer pH 7.4) were added to give concentrations of 0.05 
and 0.10 mM. After each addition the rate of oxygen consumption was 
recorded. 
2.6 Testing of daunorubicin and related compounds for activity against 
Jrypanosoma rhodesiense 
The work described in this section was carried out by Dr. J. Williamson 
and Mr. T.J. Scott-Finnigan (N.I.M.R., London, England). 
2.6.1 Materials 
Kreb's glucose and citrate saline solution were prepared as described 
in Appendix I. Microtest II plates were purchased from Falcon Plastics 
(California, USA), and automatic microlitre pipettes were purchased 
from Gibson Ltd. (Villiers-Ie-Bel, France). 
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2.6.2 Animals 
Parkes mice (20-2Sg), fed on laboratory diet 41B (Pilsbury's, 
Birmingham, England) were used ~n all experiments. 
2.6.3 Passaging of Trypanosoma rhodesiense 
Trypanosomes prepared as described in section 2.5.4 were suspended 
in citrate saline solution, and the concentration was adjusted to 
40,000 parasites/ml using a haemacytometer. An aliquot (O.S ml) was 
injected intraperitoneally into a mouse. Death occurred three days 
after infection. 
2.6.4 Preparation of ~rypanosomes for in vitro and in vivo drug assays 
Blood (0.7 ml) was removed ffrom an ether-anaesthetised mouse, 
mixed with citrate saline solution (0.3 ml), placed in a centrifuge tube 
together with further citrate saline (S ml), and centrifuged at 600g 
for ten minutes. The supernatant was removed with a Pasteur pipette, 
the white trypanosome layer was transferred to a fresh centrifuge tube, 
made up to 10 ml with Kreb's· glucose solution and centrifuged at 600xg 
for five minutes. This washing procedure was repeated; the trypanosome 
pellet was finally resuspended in a convenient volume of Kreb's glucose: 
rat serum (1:1, pre-warmed to 37°C). 
2.6.S In vitro testing of daunorubicin and related compounds against 
Trypanosome rhodesiense 
In vitro testing was carried out as previously described (Williamson 
and Scott-Finnigan, 1978) and was as follows: 
Infected blood (1 drop) was added to a solution of inactivated 
calf serum and Kreb's glucose solution (S ml, 1:1). The concentration 
was measured using a haemacytometer and adjusted to 107 parasites/mI. 
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Aliquots (0.18 ml) of inactivated calf serum and Kreb's glucose solution 
were distributed 1n a Microtest II plate. Medium (0.2 ml) containing 
drug (10-3M) was placed in one well and an aliquot (20 ~l) of this 
solution was transferred to a second well containing medium (0.18 ml) 
using an automatic pipette. The drug was serially diluted in the 
. f . (10-3 -10) other wells to g1ve a range 0 concentrat10ns -10 M. After 
adding trypanosome suspension (20 ~l) and incubating for four hours 
at 37°C, trypanosome numbers and motility were assessed using an 
inverted microscope (ocular x 10, obj ective x 40) . Infectivity was 
checked by intraperitoneal injection of the well contents into mice 
(one mouse per well) which were subsequently examined daily for development 
of parasitaemia. Injection of untreated control suspensions was invariably 
fatal within four days. Total abolition of infectivity was concluded 
if no parasites were detectable over a period of 30 days, blood being 
considered negative if no trypanosomes were seen in 30 microscope 
fields (ocular x 8, objective x 40) in a coverslip preparation of a drop 
of blood. Negative parasitaemia followed by a relapse was considered 
as a temporary abolition of infectivity. 
2.6.6 In vivo testing of daunorubicin and related compounds against 
Trypanosoma phodesiense 
Infected mice were injected intraperitoneally (0.5 ml/mouse) with 
aqueous drug solution. Subsequent parasitaemia was followed daily by 
microscopic examination of tail blood (objective x 40, ocular x 8) in a 
coverslip preparation. Absence of trypanosomesin 30 microscope fields 
for at least 30 days was taken as criterion of cure. Intermediate drug 
effects ranged from: 
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1) None (treated mice died as rapidly as controls, without 
showing any reduction in parasitaemia). 
2) Treated mice survived longer than controls without showing 
clearance of parasites from the blood. 
3) Treated mice survived longer than controls and showed 
temporary clearance of parasites from the blood (relapse). 
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CHAPTER 3 RESULTS AND DISCUSSION 
3.1 Preparation of daunorubicin conjugates and related compounds 
3.1.1 Doxorubicin-14 stearate 
Daunorubicin in vitro is one of the most active trypanocidal agents 
known, and abolishes the infectivity of T.b. rhodesiense at nanomolar 
concentrations, but is totally inactive against trypanosomes in vivo 
(Williamson and Scott-Finnigan, 1978). An investigation of this lack of 
activity s~owed that, although daunorubicin reaches the parasite 1n 
concentrations greatly in excess of that required for activity in vitro, 
its presence is only transitory (Brown et al., 1982a). Since lipophilic 
pro-drugs are in many cases known to be excreted more slowly than the 
parent drug (Bundegaard and Hansen, 1981), it was hypothesized that 
administration of a lipophilic pro-drug derivative would delay clearance 
of drug from the body and might produce a trypanocidal effect. Also, 
since the anthracyclines are known to accumulate by diffusion process 
1n tumour cells and possibly in trypanosomes (Skovsgaard, 1977; Brown 
et al., 1982), a lipo~hilic pro-drug would also be expected to enhance 
drug accumulation by the parasite. Enhanced uptake of the lipophilic 
anthracycline carminomycin by tumour cells has been observed by Kessel 
(1979). Bachur (1976) has demonstrated a relationship amongst the 
anthracycline drugs between partition coefficient (lipophilicty) and 
drug uptake by tumour cells. 
The first pro-drug to be prepared was doxorubicin-14 stearate (Figure 3.1), 
using the method of Arcamone et al. (1974) for the preparation of 
14-0-octanoyl and related derivatives of doxorubicin (section 1.4). 
Arcamone et al. (1974) demonstrated that doxorubicin-14 esters 
had high octanol/water partition coefficients and were rapidly 
hydrolysed to doxorubicin by bloodstream esterases. Lenaz et al. 
(1974) have suggested that the ester group is hydrolysed intracellularly, 
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Figure 3.1 o o 0 









Doxorubicin-14 stearate, a lipophilic pro-drug 
thus the stearate group might act as a transmembrane carrier. 
T. rhodesiense shows a unique and rapid uptake of stearic acid (Dixon 
et al.,. 1971), hence enhanced uptake and cleavage of doxorubicin-14 
stearate might be expected. The parent drug doxorubicin is also a 
highly active trypanocidal agent in vitro, but lacks in vivo activity 
(Williamson and Scott-Finnigan, 1978). The mass spectrum of doxorubicin-14 
stearate is presented in Figures3.2 and 3.3. The heaviest fragment, 
which occurs at mle 441 is formed after loss of the daunosamine sugar 
group and the stearate side chain (Williams and Fleming, 1973) •. The 
mass fragment at m/e 362 also occurs in the mass spectrum of daunorubicin 
(Figure 3.3) and its aglycone daunomycinone (Arcamone et a1., 1969) and 
is the 7-deoxyaglycone. In the mass spectrum of daunorubicin-14 
stearate, the ions at mle 380 and mle 362 might arise from an intra-
molecular rearrangement (with elimination of carbon dioxide and a 
hydroxide radical, followed by loss 'of water (Figure 3.2».. Further 
identification of doxorubicin-14 stearate is provided by the infrared 
spectrum. The absorption band for the ester carbonyl group is found at 
1736 cm- 1 • Arcamone et ale (1974a) found this group to lie in the 
. -1 
range 1730-1725 cm for aliphatic doxorubicin-14-acyl derivatives. 
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Figure 3.2: Mass spectral fragmentation pattern of doxorubicin-14 stearate 
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Figure 3.3: Mass spectrum of doxorubicin-14 stearate 
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-1 In contrast, the C-13 carbonyl peak occurs at 1715 cm in the infrared 
spectrum of daunorubicin and doxorubicin (Smith et al., 1977). Quinone 
carbonyl groups occur at about 1600 cm- 1 
The three aromatic protons of doxorubicin-14 stearate occur in 
the NMR spectrum at between 7.4 and 8.8 (Figure 3.~ and have an integral 
height of 5 mm, hence one proton has an integral height of 1.6 mm. 
The major peak at 1.358 is due to the stearate group and consists of 
approximately 26 protons. Other protons of the stearate group occur 
within the multiplet between 0.8 and 2.68. The protons at position C-14 
of daunorubicin occur at 2.38 (Figure 3.5), but in this derivative, 
the protons at C-14 are shifted to approximately 3.48 (Williams and 
Fleming, 1973) due to the deshielding effect of the ester group and 
occur as part of the multiplet between 3.4 and 3.68. The details of 
the other N.M.R. peaks are presented in section 2.25. 
Doxorubicin-14 stearate was tested against Trypanosoma rhodesiense 
in vitro (section 3.3) but was found to be inactive. Attention was 
then turned to the development of daunorubicin macromolecule conjugates 
as pro-drugs. 
A second approach to the development of an effective trypanocide 
daunorubicin derivative was through the use of macromolecular carriers. 
Drug-carrier conjugates have been used to sustain release of otherwise 
rapidly excreted drugs (Bundegaard and Hansen, 1981), and also to alter 
drug distribution in the body (Gros et al., 1981). Ferritin and 
albumin were chosen as potential carriers, since they are endocytosed 
by trypanosomes (Brown et a1., 1965; Fairlamb and Bowman, 1977), and 
therefore intracellular accumulation of bound drug would be expected. 
Bovine serum albumin was chosen as a macromolecular carrier for the 
initial studies as it is readily available commercially and possesses 
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was prepared by a method utilising periodate oxidation of the 
daunosamine sugar group of daunorubicin, followed by reduction of the 
Schiff's base formed between drug and BSA, using sodium borohydride 
(Hurwitz et al., 1975). The product was passed through a Sephadex G50 
gel filtration column to separate conjugate from free drug, and was then 
freeze-dried. Since albumin is a carrier protein which possesses non-
covalent binding sites for small molecules (Berde et al., 1979) to which 
daunorubicin could bind, the stability of the conjugate was tested 
using gel chromatography in 1M sodium chloride and in 2% sodium dodecyl 
sulphate in 8M urea, to disrupt ionic, hydrophilic and hydrogen bonding. 
In each test all of the drug was eluted in the void volume of the 
column, indicating that it was covalently bound to the carrier under 
these conditions. 
This conjugate was tested against T. rhodesiense in vitro, but 
was found to be inactive (Table 3.5). A possible explanation for 
this lack of activity is that the conjugate linkage is insufficiently 
labile to provide trypanocidal levels of free daunorubicin (Soudjin, 
1977), and the conjugate itself being active. Loss of basic character 
of the drug, 
1 1 
due to cleavage of the C3 - C4 bond due to periodate 
oxidation, may also be a cause of this inactivity since Di Marco and 
Arcamone (1975) have shown that N-acylation, which reduces the basic 
character of daunorubicin, is accompanied by a reduction in antitumour 
efficacy. 
A conjugate waS then prepared in which daunorubicin was linked 
to bovine serum albumin using a succinyl spacer group (Figure 3.1.6) 
linked to drug and protein by amide bonds. This would produce an N-acyl 
product which is stable since such amide bonds are not readily hydrolysed 
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~igure 3.5: 250 MHz spectrum of daunorubicin hydrochloride. 
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succinylated by reaction with succinic anhydride (Trouet et al., 1982) 
and dialysed to remove unreacted succinic acid. The succinylated protein 
was isolated by freeze-drying. Daunorubicin was added to a solution of 
the derivatised protein and linked using a condensing agent, to form an 
amide bond. 
Daunorubicin-NH-C- (CH )-C-NH- BSA. 
II 2 II 
o 0 
Figure 3.6: Structure of daunorubicin-bovine serum albumin linked 
via a succinyl spacer group. 
The product was stable to 1M sodium chloride and 2% sodium dodecyl 
sulphate in 8M urea. When tested against T.b. rhodesiense in vitro 
(section 3.4) this conjugate was inactive. Stability of this conjugate 
was tested in phosphate buffered saline, murine plasma and trypanosomal 
homogenate, the conjugate was found to be refractory to breakdown in 
all three media tested (section 3.3). Hence, stable drug conjugate 
linked via the amino groups are inactive. 
In order to provide a conjugate in which daunorubicin would be 
released unchanged from a labile linkage, a conjugate was prepared using 
glutaraldehyde as the linking agent. Glutaraldehyde is known to react 
with amino groups and should form a stable Schiff's base which is 
susceptible to hydrolysis. 
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Daunorubicin- N= C-(CH )-C=N-BSA 
H 2~ H 
Figure 3.7: Theoretical structure of daunorubicin-bovine serum albumin 
conjugate linked via a glutaraldehyde spacer group. 
A conjugate prepared, using glutaraldehyde, was therefore expected to 
release daunorubicin as the unchanged drug. Later work (section 3.3) 
in fact indicated that the structure of the conjugate was more complex 
than that shown in Figure 3.7. This conjugate was active in vivo 
(Table 3.2.3) RS well as in vitro (Table 3.3.1) prolonging 
the lives of mice infected with Trypanosoma rhodesiense up to ten days 
after initial infection. The conjugate also cleared trypanosomes from 
the bloodstream of the infected animal when given in doses of 7.5 mg/kg 
of drug and above (Table 3.3.3). However, no cures were obtained. 
In order to optimise the efficacy of daunorubicin macromolecule 
conjugate, two lines of investigation were pursued: 
1) Variation of the type of carrier macromolecule in order to 
identify the characteristics required for optimum uptake of 
the conjugate by trypanosomes. 
2) Variation of the daunorubicin macromolecule linkage and 
determination of drug release with time so as to identify 
the characteristics of the linkage required for activity. 
The macromolecules used were chosen with regard to their different 
physical and chemical characteristics. Daunorubicin was linked via 
glutaraldehyde to ferritin, apoferritin, histone, and dextran derivatised 
to contain amino groups. These macromolecules provide a range of 
molecular weights and electrical charge. The characteristics of the 
resulting conjugates are shown in Table 3.1; all of these conjugates were 





Macromolecule Molecular Characteristics Daunorubicin % saturation* Trypanocidal 
Weight loading of protein 
(x 10-3) (drug/mg protein) 
None 
Bovine serum 69 Globular Protein 18 3.6, 
albumin (neutral) 
Horse spleen 900 Globular Protein 55 3.8 
ferritin (acidic) 
Horse spleen 440 Globular Protein 20.5 0.7 
Apoferritin (acidic) 
Calf Thymus 10 Globular Protein 19.7 -
Histone f1 (basic) 
Polyamino- 40 Polysaccharide 8.6 - ! 
dextran (basic) 
----- ---
* Determined from the molar ratio of drug to protein and expressing this as a percentage of the 





















3.1.2 Daunorubicin-ferritin conjugate 
Ferritin was of particular interest as a carrier, S1nce Brown et al. 
(1965) observed in vitro uptake of ferritin by Trypanosoma rhodesiense. 
Ferritin contains a core of ferric hydroxide surrounded by twenty-four 
sub-units of apoferritin and can be prepared from apoferritin and 
ferrous ion in the presence of an oxidising agent (Crichton, 1973). 
Since daunorubicin forms a stable complex with iron (Gosalvez, 1977), 
preparation of daunorubicin-ferritin complex by sequestration of 
daunorubicin in the ferritin core was attempted. Daunorubicin would 
be expected to be released from the ferritin when the complex is 
endocytosed and probably metabolised by trypanosomes (Langreth and 
Ba1ber, 1975). Oxidation of ferrous sulphate in the presence of 
apoferritin and daunorubicin produced a conjugate which was stable to 
1.0M sodium chloride and 2% sodium dodecy1 sulphate in 8M urea, although 
drug was released after reduction of ferritin with 1% thioacetic acid. 
This conjugate possessed a very high drug loading (121 pg/mg ferritin), 
but was inactive in vivo. This may be due to the high stability of the 
daunorubicin iron complex. 
3.1.3 Daunorubicin conjugate linked via the C-13 carbonyl group 
Although conjugates prepared using glutaraldehyde were active, it 
is not an ideal linking agent. Due to its bifunctional nature, protein 
cross-linking can occur which may lead to loss of solubility and, if 
antibodies are used as the carrier, to loss of specificity (Hurwitz et al., 
1975). In addition, since this method requires a primary amine group, 
daunorubicin derivatives which do not contain such a group cannot be used. 
In order to circumvent these problems, and to investigate the 
characteristics of the linkage required for optimum activity, an attempt 
was made to develop further conjugates by exploiting the carbonyl group 
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at position C-13 of daunorubicin. The linking agents 1,4-hydrazino-
benzoic acid and aminoCoxy)acetic acid were chosen as they readily react 
with carbonyl groups to give a hydrazone and an oxime respectively 
(Erlanger, 1976). The linking agent was coupled to bovine serum albumin 
via an activated ester of the acidic function using a carbodiimide to 
form an amide bond (see Figures 3.8(a) and (b». Prior to this, the 
basic moieties of the cross-linking agents were protected by tri-
fluoracetylation since self-condensation of the linking agent would 
occur. Subsequent to the coupling to protein, trifluoroacetyl grou~s 
were removed by mild hydrolysis under basic conditions. 
During this procedure, bovine serum albumin was not 
apparently denatured since no precipitation of material was observed. 
Incubation of daunorubicin with 1,4-hydrazinobenzoic acid and 
amino(oxy)acetic acid linked to bovine serum albumin produced conjugates 
which were unstable (section 3.3) and were not active in vivo. 
3.1.4 Glyoxylic acid linked daunorubicin conjugate 
Glutaraldehyde is known to form at least two types of linkage 
between protein and drug (section 3.3). The lability of this type of 
linkage will probably be different from that of a simple Schiff's base 
linkage, since a glutaraldehyde linkage might rearrange to form an 
enamine (Sollenberger and Martin, 1968). Simple Schiff's bases are 
known to be reversible (Sollenberger and Martin, 1968), and a drug-
protein conjugate linked by a simple Schiff's base would be expected 
to release drug rapidly in vivo and so might produce a trypanocidal 
effect. Glyoxylic acid was chosen as a potential linking agent as the 
carboxyl group may be linked to the carrier molecule and daunorubicin 
may be linked to the aldehyde group via Schiff's base formation. 
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Figure 3.8(a): Preparation of daunorubicin-bovine serum albumin conjugate, linked via: a) 1,4-hydrazinobenzoic acid 
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Figure 3.9: Attempted preparation of daunorubicin-dextran conjugate linked via glyoxylic acid 
must be protected against nucleophilic attack by the condensing agent. 
The sodium salt of glyoxylic acid hemiacetal (sodium-2-methoxy-2-
hydroxyacetate) was synthesised (section 2.1.9(c» as these compounds 
are known to be readily hydrolysed by dilute acid, to give the aldehyde 
group. Elemental analysis and other data presented in section 2.1.9(c) 
support the formula given. In order to find the condition necessary 
to generate glyoxylic acid, a small sample was heated with dilute acid 
for two hours. The water was removed by evaporation under vacuum and 
the infrared spectrum of the product was recorded (Figure 3.10b). The 
spectrum shows marked changes from that of the starting material 
(Figure 3.10b) and several of the major peaks are characteristic of 
-1 
glyoxylic acid, including aldehyde stretch at 1730 cm (Figures 3.1.10b 
and 3.1.11). Some peaks characteristic of the starting material are 
still present, indicating that hydrolysis is not complete. Under the 
conditions required to generate glyoxylic acid, proteins would be 
denatured and are therefore unsuitable as carriers. Cyanogen bromide 
activated 1,3-diaminopropyl-dextran was used as the carrier since 
cyanogen bromide activated conjugates are known to be stable in acid 
solutions- (Axen et al., 1967). Preparation of the conjugate proceeded 
as described in section 2.1.6(g), for reaction sequence see Figure 3.9. 
However, a product could not be isolated by Sephadex gel chromatography, 
presumably due to rapid hydrolysis of the Schiff's base linkage. 
3.1.5 Comparison of the absorbance and fluorescence methods for the 
measurement of daunorubicin in macromolecular conjugates 
In accordance with earlier workers (Hurwitz et al., 1975) the drug 
content of conjugates was found by measurement of absorbance at 495 nm 
using an extinction coefficient (E~:m) of 196. This may not give an 
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Figure 3.11: Infrared spectrum of glyoxylic acid 
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free drug. Linkage of drug to a macromolecule may also alter the 
extinction coefficient. In order to demonstrate whether this method 
gave a reliable estimate of the amount of drug bound, an independent 
method of drug estimation was developed (section 2.1.8) based on 
hydrolysis of drug aglycone from the carrier, followed by fluorimetric 
determination of the aglycone. A calibration curve prepared using 
aqueous daunorubicin solution is shown in Figure 3.12. The correlation 
coefficient was greater than 0.999. A daunorubicin-bovine serum albumin 
conjugate was analysed by both methods and the results are presented 
in Table 3.2. 
Table 3.2: Comparison of the daunorubicin content of five samples of 
a BSA conjugate analysed by spectrophotometric and 
fluorimetric methods 
Sample Weight (mg) Concentration of daunorubicin ! 
(IJg mg- 1) 
, 
measured by: i 
Absorbance Fluorescence ! 
1 8.282 13.7 15.3 
2 6.126 13.6 14.6 
3 6.912 13.5 15. 1 I 
I 
4 10.021 9.4 6.1 
! 
5 8.672 13.2 13.9 
Mean = 12.68 13.0 
Standard deviation = 0.83 1.7 
Analysis using student's t-test indicated no significant difference 
between these methods (p = 0.05). If Sample 4, which appears to be 
anomalous, is excluded, the mean become 13.7 and 14.7 for the absorption 
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Figure 3.12: Calibration curve for fluorescence assay of daunorubicin 
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that the difference between the means was not significant. These results 
show that these methods produce similar results, and that differences in 
sample homogeneity are greater than differences between the assay methods. 
3.1.6 Preparation of N-acety1daunorubicin 
N-Acetyldaunorubicin was prepared by the method of Yamamoto et a1. 
(1972). This derivative is similar in structure to daunorubicin, but 
was found not to intercalate into DNA, and was used to compare the 
effect of a non-intercalating daunorubicin derivative with that of 
daunorubicin. The NMR spectrum (Figure 3.5.1) is identical with that 
published by Arcamone et al. (1969) except for a peak at 3.58 <5. This 
peak is also present in the NMR spectrum of daunorubicin (Figure 3.13) 
and is probably due to water, which does absorb in this region 
(Williams and Fleming, 1973). The melting point of 172°C is in the 
middle of the range of 166-177°C reported for N-acetyldaunorubicin by 
Yamamoto et a1. (1972). The mass spectrum of N-acetyldaunorubicin does 
not contain peaks above mle 171; however there is a series of peaks 
present in the mass spectrum which are characteristic of this compound 
(Figures 3.14 and 3.15). 
This chapter has shown the rationale behind developments of 
daunorubicin derivative and macromolecular conjugates and given some 
indication of their activity against T. rhodesiense. In the following 
















Figure 3.13: 250 MHz NMR spectrum ~f N~acetyldaunorubicin in CDCl 3 
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Figure 3.15: Mass spectrum of N-acetyldaunorubicin nn/e 
3.2 Testing of daunorubicin and related compounds against TrYDanosoma 
rllOdesiense in vitro and in vivo 
All testing for trypanocidal activity described 1n this section was 
performed by Dr. J. Williamson and Mr. T.J. Scott-Finnigan. (N.I.M.R., 
Mill Hill, London). 
The in vitro screening test described 1n section 2.6.4 was developed 
for rapid screening of drugs for potential trypanocidal activity. In 
this simple assay method inhibition of motility has been shown to 
correlate well with inhibition of respiration and glycolysis (Williamson 
et al., 1975). Infectivity 1n mice has been used as an index of cell 
division as the monomorphic form of Trypanosoma rhodesiense used in this 
assay does not multiply in vitro. The two types of activity assessed 
indicate whether a trypanocidal agent is acting on energy producing 
reactions, or on macromolecular synthesis. A strong link between the 
anti-tumour and trypanocidal activity of drugs is well known (Kinnamon 
et al., 1979; Kandaswamy and Henderson, 1962), and this assay method was 
used to screen a number of anti-tumour agents for trypanocidal activity 
(Williamson and Scott-Finnigan, 1978, 1975) and revealed uniquely high 
activity for daunorubicin. The results of in vitro screening for a 
series of anthracycline antibiotics is presented in Table 3.3. High 
activity against trypanosomes, as shown by permanent loss of infectivity 
appears to be peculiar to daunorubicin, although the closely related 
drug doxorubicin, as well as nogalamycin and 7-0-methylnogarol show high 
temporary inhibition of infectivity. The locus of action appears to be 
macromolecular synthesis, rather than energy producing metabolism as 
only doxorubicin strongly inhibited motility. Strong inhibition of 
infectivity is expected as drug nuclear DNA association is believed to 
be involved in the cytotoxic action of daunorubicin (Henry, 1976). 
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Table 3.3: In vit~o activity of anthracyclines and related compounds 
against Trypanosoma ~hodesiense 
Drug Loss of 1 Loss of infectivity 1 
motility 
Temporary Permanent 
Daunorubicin hydrochloride 4 11 10 
5-Iminodaunorubicin hydro- < 3 4 < 3 
chloride 
N.N-Dibenzyldaunorubicin 3 < 3 < 3 
hydrochloride 
N-Acetyldaunorubicin II < 3 5 < 3 
4-Deoxydaunorubicin 5 6 3 
hydrochloride 
4-Demethoxydaunorubicin 5 5 3 
hydrochloride 
3.4-Diepidaunorubicin 5 > 10 > 10 
hydrochloride 
Doxorubicin hydrochloride 8 > 10 4 
Doxorubicin-14 stearate /1 3 < 3 3 
hydrochloride 
4-Deoxydoxorubicin hydrochlorid ~ 5 > 6 3 
Nogalamycin 4 > 9 6 
7-con-O-Methylnogarol 4 8 < 3 
Daunorubicin-bovine serum * 4 4 < 4 
albumin (p) 
Daunorubicin-bovine serum ** < 4 >10 > 10 
albumin (G) 
Daunorubicin-ferritin (G) ** 4 9 6 
-1) The values given are maximum titres (log10M producing the 
trypanocidal effect j drugs with titres < 3 are considered inactive . 
~. 
* 'p' denotes that the periodate oxidation method (section 2.1.2) was used. 
** IG' denotes that the glutaraldehyde coupling method (sction 2.1.6) 
was used. 
# see section 2.2 for synthesis of these compounds. 
- 112 -
In contrast to the wide range of activity shown by the anthracyclines 
in vitpo. none of the drugs tested in vivo showed any activity CTable 3.4). 
Table 3.4: Activity of anthracyc1ine drugs in mice infected with 
Trypanosoma ~hodesiense 
Dose Number of Mean prolongation I 
" (mg/kg) mice used of infection (days) ; 
Drug 
Daunorubicin r 30 2 0 
Daunorubicin 20 2 0 
Daunorubicin 15 15 0 
Doxorubicin 30 4 0 




1.5 5 0 
N-Acety1daunorubicin 
~-Acety1daunorubicin 
Brown et a1. (1982) showed that uptake of daunorubicin is transitory, 
hence it was thought that increasing the retention of the drug by 
preparing a sustained release form of daunorubicin might lead to a 
trypanocidal effect. This was attempted by linking drug to a macro-
molecular carrier. Glutaraldehyde ~as chosen as a linking agent since 
SChiff's base linkages are known to be labile, and would be expected to 
readily release daunorubicin. Daunorubicin-bovine serum albumin 
conjugate linked via glutaraldehyde was active in vit~o (Table 3.3) and 
also in vivo (Table 3.5). This conjugate prolonged the life of infected 
mice by several days, and also cleared trypanosomes from the bloodstream. 
However, no cures were obtained. In order to increase the efficacy of 
anthracycline conjugates three lines of research were explored which 
were: (a) variation of the macromolecular carrier; (b) variation of the 
drug-macromolecule linkage and (c) variation of "the anthracycline used. 
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Table 3.5: Activity of glutaraldehyde linked daunorubicin macromolecule 
conjugates in mice infected with Trypanosoma rhodesiense 
Conjugate 
Bovine serum albumin 
" " " 
" " " 
" " " 
" " " 
Bovine serum albumin 
(Fraction 1) 
Bovine serum albumin 
(Fraction II) 
Glutarated bovine serum 
albumin (2500 mg/kg) 











Calf thymus histone f, 
Diaminopropyldextran 



































(days) ± (S.D.) 
0.9 (0.5) 1,2 
2.9 (0.83) 
3.9 (0.54) 1 
1.8 (0.6) 
1.2 (0.4) 











Trypanosomes cleared temporarily from the bloodstream. 




Table 3.6: Activity of daunorubicin-protein conjugates in mice infected with Trypanosoma rhodesiense 
Daunorubicin Conjugate Linkage Dose of drug Number of mice Mean prolongation of 
component used infection (days + S. D.) 
(mg/kg) 
Bovine serum albumin Glutaraldehyde 15 10 2.9 (0.83) 
Bovine serum albumin Succinyl (amide) 15 4 0 (0) 
Bovine serum albumin Aminooxyacetic acid 15 15 0.4 (0.8) 
(oxime) 
Bovine serum albumin Hydrazinobenzoic acid 15 4 0.5 (0.5) 
(hydrazone) 
Ferritin Chelate 15 10 0.2 (0.4) 






These conjugates were weakly active, prolonged the infection of 
only a few of the mice tested, and did not clear trypanosomes from 
the bloodstream of the infected mice. 
Glutaraldehyde-linked bovine serum albumin conjugate, prepared 
using anthracyclines other than daunorubicin, were also active (Table 
3.7), although none was as active as daunorubicin. 
Table 3.7: Activity of anthracycline-bovine serum albumin conjugates 
in mice infected with Trypanosoma rhodesiense . 
Drug Dose of drug Number of Prolongation of 
component mice used infection 
(mg/kg) (days ± S.D.) 
Daunorubicin 15 10 2.9 (.83) 
4-Demethoxydaunorubicin 15 10 2.4 (.916) 
4-Deoxydaunorubicin 15 3 2.0 ( 1.4) 
5-Iminodaunorubicin 15 5 2.0 
7.5 5 0.0 (2) 
Doxorubicin 15 10 1.5 (0.5) 
4-Deoxydoxorubicin 15 2 0.5 (0.5) 
3,4-Diepidaunorubicin 15 1.0 (0) 
Daunorubicin was the most potent anthracycline drug tested in 
vi t ro , but all of the anthracyclines were inactive in vivo . However, 
as a glutaraldehyde-linked conjugate, daunorubicin was also the most 
active drug tested, but there was no obvious relationship between in 
vitro , activity of the drugs and the in vivo activity of the glutar-
aldehyde linked conjugates. Glutaraldehyde-linked daunorubicin Dovine 
serum albumin conjugate cleared trypanosomes from the bloodstream of 
infected mice and prolonged the course of infection, but no cures 
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were obtained. Linking agents, other than glutaraldehyde, produced 
conjugates which were only weakly active in vivo. 
The strain of T. rhodesiense used in these experiments has been 
maintained by syringe passage for 35 years (Yorke et al., 1929) and 
consists solely of long, thin, forms. This strain cannot be considered 
representative of wild strains, hence daunorubicin-BSA-conjugate was 
also tested against a variety of trypanosome strains. The results 
are given in Table 3.8 
Table 3.8: Activity of glutaraldehyde-linked daunorubicin bovine 
serum albumin in mice infected with various trypanosome 
strains . 
, 
Trypanosome strain I Dose (mg/kg) Number of Mean prolongation 
mice used of infection (days) 
T. bruaei (427) 15 10 I 6.4 
" 7.5 8 5.6 I 
" (serengeti) 3.7 10 3.0 
" (serengeti) 15 10 0.3 
T. rhodesiense 15 10 2 .8 
(Stilbamidine resistant) 
" 7.5 10 9.8 
T. aongolenae 15 10 3.8 
Glutaraldehyde-linked daunorubicin-BSA conjugate was active against 
all strains of trypanosome tested. The strain used did have an effect 
on the prolongation of infection, since the conjugate was only slightly 
active against T. bruaei (serengeti) strain. Infection was prolonged 
to at least 18 days longer than untreated controls, but no cures were 
obtained. Cures would be expected, since this conjugate clears 
trypanosomes from the bloodstream. Abolarin et al. (1982) showed that 
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T. b~ucei enter the ependymal cells of the choroid plexus, which 
constitutes part of the blood-brain-barrier. This might protect the 
intracellular trypanosomes from the effect of macromolecule conjugates 
since neither macromolecules nor freedaunorubicin will cross the blood-
brain-barrier (May et al., 1980). The intracellular form may re-enter 
the bloodstream and re-establish the infection. This intracellular 
form may restrict the usefulness of conjugates in the treatment of 
this disease. Similar intracellular forms are present in Chagas disease 
and have prevented the development of effective chemotherapeutic agents. 
3.3 In vit~o breakdown of daunorubicin-macromolecule conjugates 1n 
biological fluids 
Daunorubicin-macromolecule conjugates have been evaluated in 
numerous cancer studies (Levi-Schaffer et al., 1982; Hurwitz et al., 1975; 
Bernstein et al., 1978; Monsigny et al., 1980). However, little 
attention has been paid to the stability of the linkage between drug 
and carrier. In vitro and in vivo testing of a variety of daunorubicin-
macromolecule conjugates(section 3.2) revealed that conjugates differing 
only in the type of linkage used may have widely differing activities 
against T. rhodesiense. The nature of the linkage is thus of great 
importance in understanding the way in which conjugates exert their 
cytotoxic effects. Daunorubicin macromolecule conjugates (linked via 
glutaraldehyde) may be postulated to act (i) to transport daunorubicin 
prior to release of free drug in the bloodstream or after ingestion by 
the parasite, and/or (ii) by acting as a trypanocide without release 
of drug. There is, therefore, a need to investigate whether drug can 
be released under physiological conditions in order to more fully 
understand the mechanism of action and, hence, design more effective 
conjugates. 
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Methods for the determination of daunorubicin and its metabolites 
have usually involved extraction from a basified sample. Determination 
has been by HPLC usinR fluorescence detection (Hulhoven and Desager, 
1976; Israel et al., 1978; Brown et al., 1981 ). A method was developed 
based on extraction from a basified solution followed by fluorescence 
detection (see section 2.3.4). Calibration curves were prepared by 
extraction of known concentrations of daunorubicin from phosphate 
buffered saline and murine plasma. The extraction efficiency was taken 
as 100% since following the extraction procedure the remaining solution 
of phosphate buffered saline did not absorb light at the A of max 
daunorubicin (495 nm). Extraction of daunorubicin from murine plasma 
or trypanosome homogenate could not be tested in this way due to light 
scattering by the solution. Linear calibration was obtained and 
regression analysis gave correlation coefficients greater than 0.997 
(see Figure 3.16). 
Daunorubicin release from conjugates in phosphate buffered saline, 
pH 7.4, is illustrated in Figure 3.18. 
The fraction of drug released from daunorubicin-bovine serum 
albumin conjugate linked via glutaraldehyde depended on the concentration 
(~g/mg protein) of drug initially linked. For example, the conjugate 
containing 13.3 ~g/mg protein released 12% of bound drug after two and 
a half hours, but conjugate containing 3.9 ~g/mg protein only released 
5% of bound drug in the same time period (see Figure 3.18). In either 
case, no further drug was released, even after a five-hour incubation 
period. 
Glutaraldehyde conjugate was isolated after prolonged incubation 
as described in $cction 2.1.6.c, and free drug was removed by passage 
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Figure 3.16: Calibration curve for the f'luorescence determination of 
daunorubicin in PBS and murine plasma. 
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drug had been removed, was called fraction II glutaraldehyde conjugate, 
the material prior to incubation being called fraction I conjugate. 
As expected, there was no release of drug from fraction II 
glutaraldehyde conjugate when further incubated in phosphate buffered 
saline (Figure 3.18). Drug release from conjugates in murine plasma 
is illustrated in Figure 3.19. Fraction I glutaraldehyde conjugate 
released about 21% of bound drug, while fraction II conjugate released 
about 9%. This fresh drug release of fraction II conjugate is 
presumably due to enzymic hydrolysis of the daunorubicin-glutaraldehyde 
bond. Incubation of conjugates in trypanosomal homogenates gave 
similar results to those found for murine plasma (Figures 3.19 and 3.20). 
However, fraction I conjugate released about 35% of bound drug, while 
fraction II glutaraldehyde conjugate released about 10% of bound drug. 
These results demonstrate that the glutaraldehyde conjugate of 
daunorubicin-BSA must contain at least two different bond types, since 
drug which is not released in phosphate buffered saline is released in 
murine plasma and trypanosomal homogenate. In support of this, 
Richards and Knowles (1968) showed that glutaraldehyde exists as an 
a, S - unsaturated aldehyde in aqueous solution and reacts with amino 
groups to give a stable Michael-type adduct, as well as linkages 
containing Schiff's base bonds (Figure 3.17). 
t erO e~o { 
BSA-NH-CH-CH-CHz-CH-CH -NH-. . 
~igure 3.17: Proposed structure of the glutaraldehyde bond (Richards 
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Figure 3.20: Release of drug from daunorubicin-bovine albumin conjugates incubated in trypanosomal 
homogenate at 37°C 
7 8, 
Even after incubation in murine plasma and trypanosomal homogenate 
(Figures 3.19 and 3.20), not more than 35% of bound drug is released. 
The remaining drug may be linked to protein by a bond which is not 
susceptible to hydrolysis or 1S sterically hindered towards enzyme 
mediated hydrolysis. 
Fraction I and fraction II conjugate were both active against 
Trypanosoma rhodesiense in vivo. Fraction II was more active than 
fraction I, which suggests that the enzymically released component is 
important in the activity of these conjugates. 
Succinyl linked daunorubicin-bovine serum albumin was more stable 
to drug release than the fraction I glutaraldehyde conjugates and 
released about 3% of the total bound drug in phosphate buffered 
saline, murine plasma and trypanosomal homogenate. This result is in 
close agreement with that of Trouet et al. (1982) who showed that a 
daunorubicin-succinyl-bovine serum albumin conjugate containing 
100 ~g drug/mg protein released a total of 2.6% of bound drug when 
incubated in the presence of purified rat liver lysosomes. The high 
stability to drug release of this conjugate is expected since the 
amide bond is probably protected from attack by hydrolytic enzymes 
due to steric hindrance by the carrier protein. In addition, the 
amide bond is not in an ~ position with regard to an asymmetric carbon 
atom, which makes it a poor substitute for peptidases and proteases 
(Trouet et a1., 1982b). In the present study, it would appear that 
drug release from the succinyl-linked daunorubicin-BSA is not 
enzymically mediated since the same proportion of bound drug is 
released in all three media tested. 
The breakdown of the hydrazone linked conjugate is illustrated 
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the bound drug within a few minutes. Oxime linkage also released drug 
very rapidly, but the rate of breakdown could not be accurately estimated. 
The highly labile oxime and hydrazone linked conjugates and the 
refractory succinyl conjugate were all inactive (see section 3.2). 
Hence, it appears that an intermediate rate of release is required 
for activity and that this requirement is fulfilled by glutaraldehyde 
linkage. Drug release from glutaraldehyde conjugate is complete 1n 
two to three hours in murine plasma and trypanosomal homogenate, 
whereas hydrazone and oxime linked conjugates released 100% of bound 
drug within one hour. Succinyl linked conjugate released about 2% 
of drug within fifteen minutes, but little was released thereafter. 
Glutaraldehyde conjugate may be acting as a sustained release 
form of daunorubicin, since a trypanocidal dose of 25 mg/kg will 
release at least 12%, or 3 mg/kg of free drug over a three-hour period. 
This is many times greater than the trypanocidal concentration of 
0.05 mg/L required for in vit~o activity (williamson and Scott-Finnigan, 
1978). However, Brown et al. (1982) demonstrated that a daunorubicin 
dose of 25 mg/kg daunorubicin in vivo produces a drug concentration 
in blood plasma of 500 times the in vitro trypanocidal concentration 
over a six-hour period, although this dose is not trypanocidal in vivo. 
It is, therefore, unlikely that the in vivo activity of glutaraldehyde 
conjugates is solely due to sustained release of drug in the plasma. 
In addition to considering release of drug from the conjugate, 
it is important to consider whether the conjugate may be acting as a 
drug without prior release of daunorubicin. This hypothesis has 
received support in recent years. Tokes et al. (1982) found that 
cytotoxic doxorubicin-polyglutaraldehyde microspheres could interact 
with DNA, and Tritton and Yee (1982) found that doxorubicin linked to 
microspheres was cytotoxic, although no drug was released. 
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3.4 Interaction of daunorubicin analogues with DNA 
The anthracycline drugs are known to bind avidly to DNA by inter-
calation into the DNA double helix (Brown, 1978), and to inhibit I1NA 
synthesis 1n cell-free systems (Zunino et al., 1975) as well as in vivo 
(Di Marco et al., 1972). Hence chromosomal DNA has been assumed to be 
their site of action. DNA binding is accompanied by changes in the 
physical properties of both drug and DNA, and these changes can be 
used to assess the strength of the binding. On intercalation, there 
is a real shift in the visible absorption spectrum of the drug 
(bathochromic shift), a decrease in the extinction coefficient 
hypochromic shift), and a decreased bathochromic shift on basification, 
due to the drug passing from a hydrophilic to a hydrophobic environment 
(L~wrence, 1952). The fluorescence of the drug 1S also markedly 
quenched after binding to DNA ( Lober and Kittler, 1978). Changes 1n 
the physical properties of DNA which occur on intercalation include an 
increase in thermal denaturation temperature due to stabilisation of 
the DNA double helix by intercalated drug molecules (Kersten et al., 
1966), and increased viscosity (Zunino et al., 1972). Intercalation 
also causes unwinding of circular supercoiled DNA (Waring, 1970). 
The effect of DNA on the spectral properties of a series of 
daunorubicin analogues 1S shown in Table 3.9. The spectral changes 
which occurred can be divided into two groups, depending on whether 
the changes are similar to, or different from, daunorubicin, which is 
known to intercalate. Drugs which had similar DNA spectral properties 
to daunorubicin include 5-iminodaunorubicin and nogalamycin. \11 of 
these drugs showed an isosbestic point, large bathochromic (9-14 nm) 
and hypochromic (21-32%) shifts. They also showed a large shift on 




Table 3.9: Effect of DNA on the spectral properties of daunorubicin analogues 
I T--- -- .. 
I 
Position of Bathochromic 7. Decrease in , 
I Drug isosbestic shift (nm) (1) extinction I 
I 
point (nm) (1) coefficient 
(1) 
! 
I Daunorubicin 542 12 32 
5-Iminodaunorubicin 597 14 21 
I N-Acetyldaunorubicin 540 3 7.5 
N,N-Dibenzy1daunorubicin (2) - 10 _7(4) 
Daunorubicin-BSA (fraction II) - 0 4 (2) 
I Nogalamycin 512 9 24 
I I 7-0-Methylnogarol - 3 6 
I 
I 
(1) Drug concentration 5 x 10-SM, DNA/drug ratio 10:1 
(2) Drug concentration 2.5 x 10-SM, DNA/drug ratio 10:1 
(3) pH of 7.4 and 9.4 used 
(4) 77. enhancement of absorbance 
Bathochromic shift on 
basification (nm) (1),(3) 
DNA present DNA absent 









Figure 3.22: Spectral titration of daunorubicin-BSA conjugate with calf 
thymus DNA. DNA/drug ratios of 0, 1:1, 2:1, 5:1, 10:1-
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Figure 3.23: pH shift of daunorubicin-BSA conjugate on basification in 
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of DNA. Drugs which reacted differently from daunorubicin showed 
little change in spectral properties in the presence of DNA. This group 
of drugs included N,N-dibenzyldaunorubicin, 7.-0-methylnogarol, 
N-acetyldaunorubicin and daunorubicin BSA conjugate (fraction II). 
With the exception of N-acetyldaunorubicin, these drugs did not show 
an isosbestic point, but showed small bathochromic (0-10 nm) and 
hypochromic shifts (0-7.5%). Bathochromic shifts on basification were 
little changed in the presence of DNA. In contrast to daunorubicin, 
the spectral interaction of daunorubicin-BSA conjugate (fraction II) 
shows no isosbestic point, or significant hypochromic or bathochromic 
shift (Figure 3.24) and the bathchochromic shift on basification is 
greatest in the presence of DNA. Daunorubicin does not show any 
bathochromic shift under these conditions. On the basis of these 
tests, there is no evidence that daunorubicin-BSA conjugate interacts 
with DNA. This conclusion is supported by the results of Weisenhahn 
et al. (1977) who used spectral tests to demonstrate that a daunorubicin-
melanotropin conjugate did not interact with DNA. 
The interaction between drug and DNA can be investi~ated bv 
fluorescence titration since auenching of fluorescence in the 
presence of DNA is known to be indicative of a DNA-drug interaction 
(Calendi, et al. 1965). 
The results of fluorescence titrations are shown in Figures 3.26 
and 3.27. Drugs which show marked quenching in the presence of DNA 
include daunorubicin. 5-iminodaunorubicin. nogalamycin and 
7-0-methylnogarol. N-Acetyldaunorubicin and N,N-dibenzyldaunorubicin 
did not show this quenching of fluorescence on addition of DNA. The 
quenching observed with 7-0-methylnogarol is an anomaly. since, in 
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Figure 3.24: pH shift of daunorubicin. Drug concentration 5 x 10-
5
M 
DNA/drug ratio 10:1. 
(1) pH 7.4, (2) pH 7.4 DNA present, (3) pH 9.4 































with calf thymus DNA. 
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Figure 3.26: Fluorescence titration of calf thymus DNA with anthracycline drugs 
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Figure 3.27: Fluorescence quenching of nogalamycin and 7-0 methylnogarol in the presence of calf 
thymus DNA. A- 7-0 methylnogarol, e- nogalamycin 
A similar anomaly has been observed with the 7-R analogue of daunorubicin 
which does not intercalate~ but undergoes fluorescence quenching in 
the presence of DNA (Plumbridge and Brown, 1979). 
With the exception of bathochromic shifts on basification in 
the presence and absence of DNA, spectral tests do not unequivocally 
reveal the nature of the DNA drug interaction, since other modes of 
binding, such as electrostatic binding to the exterior of the double 
helix (Neidle, 1981) might also produce these phenomena. There is 
therefore a need for confirmatory tests to indicate whether the 
binding observed is intercalation. 
Confirmatory tests used in this study include thermal stabilisation 
of DNA in the presence of drug and the effect of drug on the electro-
phoretic mobility of supercalated circular DNA. These tests measure 
changes in the physical properties of DNA and are independent of the 
spectral properties of the drug. These changes are, with very few 
exceptions (Waring, 1970), specific for an intercalation mode of 
interaction. 
The interaction of daunorubicin with DNA stabilises the double 
helical structure of the macromolecule to thermal denaturation 
(Zunino et al., 1972). The results of the thermal denaturation study 
are presented in Table 10. Since the extinction coefficient of 
denatured DNA at 260 nm is greater than that of native DNA, the rate 
of thermal denaturation can be followed spectrophotometrically as 
the temperature of the sample is raised. This produces a sigmoid 
curve (Figure 3.28); the thermal denaturation temperature Tm is 
taken as the mid-point of the curve. The values of 6Tm obtained in 
this study are closely similar to values previously obtained by 
other workers (Table 3.10). The thermal denaturation temperature 
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. 
Table 3.10: Increase in thermal denaturation temperature (A Tm) of 
calf thymus DNA in the presence of anthracycline drugs. 
(0.003M tris, 0.018M NCl pH 7.4 buffer used, 
DNA/drug ratio 10:1) 
Drug Tm (OC) Literature Reference 
value (OC) 
Daunorubicin 14.8 ± 1.2 13.4 (1) Zunino et ale (1972) 
S-Iminodaunorubicin 9.1 ± 0.1 6.5(2) Plumbridge & Brown 
(1978) 
,N-Acetyldaunorubicin 2.1 ± 0.5 1.0 Zunino et al. (1979) 
:N,N-Dibenzyldaunorubicin 0.6 ± 0.0 1.35 Tong et ale (1979(b) 
I (3) 
jNogalamycin 14.2 ± 0.5 20 Das et al. ( 1974) 
I , 
17.5 Plumbridge i & Brown 
I (1979) I 
7-0 '~thylnogarol 1. 75 ± 0.05 - -
(1) 
10: 1 DNA/drug ratio in O.OlM Tris pH 7.0 buffer 
(2) 10: 1 DNA/drug ratio in 0.003M Tris, 0.018 NaCI pH 7.0 buffer 
(3) 
12: 1 DNA/drug ratio in 0.02M ionic strength buffer 
(4) 
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Figure 3.28: Thermal denaturation of DNA in the presence of naunorubicin 
(Thermal denaturation temperature Tm, is taken as the 
temperature corresponding to the mid-point of the 
absorbance/temperature sigmoidal curve.) 
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is ;1((l.'ctl.'U by the \):~A/Jrur. rati.o anu the ionic str(~llgth of tltl' buffer 
llSL'U, :1l1d thl..'se factors must b" CO!1s1'dor"d Wlle!1 . I ~ " ~ CL)mp.lrlng Lie results 
with earlier ""ork. Significant thermal denaturation of f):-JA occurs 1n 
the presence of d':JUnorubicin and other drugs \.Jhich are thought to 
intercalatc.~-acetyldaunorubicin, N,N-dibenzyldaunorubicin and 
7-0 methylnogarol which in spectral tests showed little evidence of 
interaction with DNA, also showed little effect on the thermal stability. 
The local unwinding of the DNA double helix which occurs on 
intercalation has important consequences , .. hen the DNA is circular. 
Covalently closed circular DNA is supercoiled, which makes the molecule 
unusually compact so that it has a high sedimentation coefficient and 
electrophoretic mobility, but a low viscosity (Neidle, 1981). When 
intercalation occurs, unwinding of the DNA relaxes thesupercoiling 
until at a critical drug concentration the DNA molecule behaves as 
the relaxed, open circular form. This change is accompanied by large 
changes in viscosity, sedimentation coefficient and electrophoretic 
mobility (l~aring and Henley, 1975; Espejo and Liebowitz, 1976). 
As further drug binding occurs, the additional unwinding forces the 
DNA molecule to adopt reverse supercoils, so that the sedimentation 
coefficient and electrophoretic mobility rise, and the viscosity falls. 
This behaviour is indicative of intercalation since drugs such as 
cyclophosphamide and berenil, which bind to DNA but do not intercalate, 
do not show these changes (Waring, 1970; Mong et al., 1979). An 
electrophoretic titration of covalently closed circular PH2-DNA in 
the presence of an intercalating drug produces a result similar to 
Fi~ure 3.29. At the critical drug concentration, the upper band of 
closed circular DNA co-migrates with relaxed nicked circular DNA 
(lower band). In contrast, Figure 3.30 shows an electrophoretic 
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Fi~u~e 3.29(a) : Electrophoretic titration of PM2-DNA with 
5-iminodaunorubicin , an intercalatin& drug 
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Figure 3.29b: Electrophoretic titration of PM2-DNA with 
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Figure 3.30: Calibration graph for malondialdehyde assay 
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titration with the non-intercalating drug 7-0-methylnogarol. This 
drug does not produce the required conformational change in PM2-DNA 
since the closed circular and nicked circular DNA bands do not co-
migrate, or migrate more closely at high drug concentrations. 
Table 3.11: Drug concentration required to unwind PM2-DNA (critical 








- means no effect 
Critical 
concentration 




This group of daunorubicin analogues can, on the basis of these 
tests, be classified into those drugs which intercalate and those which 
show little evidence of interaction with DNA. Intercalating drugs 
reacted similarly to daunorubicin in all of the tests used. These 
drugs showed marked spectral shifts and fluorescence quenching when 
titrated with DNA and a large thermal stabilisation of DNA. In 
addition, these drugs also unwound supercoiled PM2-DNA. Non-
intercalating daunorubicin analogues included N-acetyldaunorubicin, 
7-0-methyln J garol and N,N-dibenzyldaunorubicin. These showed little 
evidence of interaction with DNA and gave small spectral shifts 
little fluorescence quenching and only slight thermal stabilisation 
of DNA. They also did not cause unwinding of PM2-DNA. 
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3.5 The role of free radical generation in the trypanocidal activity 
of daunorubicin 
Intercalation of drug into DNA is considered to be the most important 
mechanism of cytotoxicity among the anthracycline drugs (Zunino et al., 
1972), although other mechanisms of cytotoxicity, most notably 
generation of free radicals via redox cycling of electrons, also may 
operate. A clinical manifestation of this type of toxicity is seen 
in the irreversible dose-related cardiotoxicity which occurs after 
administration of daunorubicin or doxorubicin (Lenaz & Page,1976). The cyto-
toxicity of some non-intercalative free radical producing antibiotics 
is demonstrated by streptonigrin and mitomycin C which are active 
against various neoplasms (McBride et al., 1966; Crooke and Brpdner, 1976) 
and are thought to act by free radical attack on DNA (Neidle, 1981). 
Trypanosomes are thought to be more susceptible than other 
eukaryotic cells to cellular damage by reactive oxygen species 
(02' OH, H202) (Meshnick et al., 1977; Boveris and Stopparni, 1977). 
Protective enzymes such as glutathione peroxidase and catalase, which 
destroy hydrogen peroxide, are present at low concentrations in 
trypanosomes (Boveris et al., 1980). Thus compounds such as S-lapachone, 
which catalyse the generation of superoxide radicals and hydrogen 
peroxide (Boveris et al., 1978), and haematoporphyrin which catalyses 
the homolytic cleavage of H202 to form OH'(Meshnick et al., 1978), 
are found to be trypanocidal. It ~y be that anthracycline mediated 
free radical generation is also important in the trypanocidal activity 
of these drugs, hence this process has been investigated. Generation 
of free radical species was monitored indirectly by measuring oxygen 
consumption {which is increased during production of superoxide 
radicals and by malondialdehyde production .. Malondialdehyde is 
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produced during lipid peroxidation, and this is stimulated by free 
radicals. The drugs daunorubicin, 5-iminodaunorubicin and N-acetyl-
daunorubicin were chosen for this study as they possess widely different 
DNA binding affinity and ability to stimulate generation of free 
radicals. 5-Iminodaunorubicin intercalates into DNA, although not as 
strongly as daunorubicin; however, N-acetyldaunorubicin interacts very 
weakly with DNA, and does not intercalate (section 3.4). The ability 
of these drugs to stimulate generation of free radicals and lipid 
peroxidation also varies widely. Daunorubicin is known to stimulate 
lipid peroxidation and generation of superoxide radicals both in vitro 
(Mimnaugh et al., 1982; Lown et al., 1979), and in vivo (Patterson et 
al., 1983). N-Acetyldaunorubicin is likely to possess similar free 
radical generating properties since both drugs contain identical 
anthranquinone moieties. In contrast to these drugs, 5-iminodaunorubicin 
does not stimulate generation of superoxide radicals (Davies et a1., 
1983), and inhibits lipid peroxidation (Mimnaugh et al., 1982). Lipid 
peroxidation was estimated by measurement of malondialdehyde using 
the method described in section 2.5.8 as malondialdehyde production by 
respiring tissues is accepted as being indicative of lipid peroxidation 
(Mimnaugh et al., 1982). Standard malondialdehyde solutions were 
prepared by acid hydrolysis of 1,1',3,3' -tetramethoxypropane. A 
graph of absorbance at 532 nm against malondia1dehyde concentration 
was prepared (Figure 3.30), and an extinction coefficient of 
1.51 x 105 M-1 cm-
1 
was calculated from the slope. This value is close 
-1 -1 
to the values of 1.53 and 1.50 M cm found by Mimnaugh et al. (1982) 
and Myers et a1. (1977), and was used throughout these experiments. 
The effect of anthracyclines on lipid peroxidation of trypanosomal 
microsomes was studied in vitro and the results are presented in tables 
3.12, 3.13 and 3.14. 
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Table 3.12: Effect of daunorubicin analogues on lipid peroxidation 
of trypanosomal microsomes in the presence and absence 


















the presence of ferric* 
ion (pmol/mg protein) 
2.9 ± 0.5 
3.3 ± 0.7 
3.3 ± 0.7 
3.4 ± 0.7 
2.7 ± 0.5 
* Results are the mean ± standard deviation of three experiments. 
Nl) - not determined. 
The amount of trypanosome microsomal lipid peroxidation found in 
the presence of drug was less than that found for the control value. 
Facchinetti et a1- (1982), who found a similar quenching effect with 
doxorubicin in rat liver microsomes, suggested that iron was needed as 
a catalyst. In the present study addition of ferric ion produced a 
5-10-fold increase in lipid peroxidation (see Table 3.12). However, 
the enhancement was independent of the drugs used as, using Student's 
t test, no significant difference between the results could be found. 
This suggested that iron-catalysis and not drug was responsible for 
this effect. 
The effect of daunorubicin analogues on lipid peroxidation of 
liver microsomal and trypanosomal fractions was also investigated 
after administration of these drugs to trypanosome infected mice in vivo. 
Mice were injected with drug (25 mg/kg) one day after infection with 
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T. rhodesiense and killed by cervical dislocation in two batches of 
four mice, four hours and twenty-four hours after drug injection. 
The livers were removed, pooled and used to prepare microsomal samples. 
Blood was taken by cardiac puncture and trypanosomes were isolated 
as described in section 2.6.3. The results are presented in Tables 
3.13 and 3.14. 
Table 3.13: Effect of daunorubicin analogues on lipid peroxidation 
of liver microsomes from anthracycline treated mice 
Drug * Time sample Concentration of 
taken (hours) malondialdehyde 
(nmol/mg protein) 
Control 24 110 
Daunorubicin 4 140 
Daunorubicin 24 124 
N-Acetyldaunorubicin 4 170 
N-Acetyldaunorubicin 24 140 
5-Iminodaunorubicin 4 94 
5-Iminodaunorubicin 24 90 
-1 * 25 mg K~ body weight 
Liver microsomes isolated from mice treated with daunorubicin or 
N-acetyldaunorubicin show a slight increase in malondialdehyde content 
compared with the control mice both after four hours and twenty-four 
hours. This very slight increase may be due either to the inability 
of these drugs to provoke significant lipid peroxidation in vivo or to 
metabolism of malondialdehyde. These results are consistent with 
those of Scheulen et al. (1981) who could not find evidence of lipid 
peroxidation stimulated by doxurubicin in rats in vivo except at a 
very high dose of 45 mg/kg. However, Myers et al. (1977) demonstrated 
lipid peroxidation in mice 48 hours after a dose of 15 mg/kg of 
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doxorubicin, which is twice the dose used in the present study. 
S-Iminodaunorubicin showed a slight inhibition of liver microsomal 
malondialdehyde formation compared to the control value. This is consistent 
with the results obtained for trypanosomal microsomes (Table 3.12). 
The results for trypanosomal homogenate from trypanosome infected, 
anthracyc1i r.E. treated mice are presented in Table 3.14. 
Table 3.14: Effect of daunorubicin analogues on lipid peroxidation 
of trypanosomal homogenate after isolation of 



















All of the drugs tested showed a great enhancement of lipid 
peroxidation in trypanosomes after 24 hours compared with the livers 
from trypanosome infected mice. Trypanosomes .are known to contain a 
high concentration of hydrogen peroxide due to a lack of catalase 
(Meshnick et al., 1977). Hydrogen peroxide can form the highly reactive 
hydroxyl radical by reaction with the superoxide radical (see section 
1.4.2). Since both superoxide and hydroxyl radicals are thought to be 
involved in the initiation of lipid peroxidation (Kappus and Seis, 
1981), trypanosomes may be highly susceptible to lipid peroxidation, 
and enhancement of these processes in the presence of superoxide 
generating anthracyclines is likely to occur. N-Acetyldaunorubicin 
produced the greatest increase in malondialdehyde formation in vivo 
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this being almost six times as great as that caused by daunorubicin. 
N-Acetyldaunorubicin is more lipophilic than daunorubicin and may be 
preferentially accumulated in the trypanosomes in vivo. 
Measurement of oxygen consumption can be used to detect redox 
cycling by the anthracycline antibiotics since generation of superoxide 
radicals effectively increases oxygen consumption over the basal rate. 
This has been demonstrated for daunorubicin and doxorubicin by Goodman 
and Hochstein (1977), using purified enzymes, who showed that incubation 
of daunorubicin or doxorubicin with P450 reductase and NADPH causes a 
great increase in basal rate oxygen consumption. A preliminary experiment 
was carried out to establish whether enhanced oxygen uptake in the 
presence of anthracyclines could be demonstrated in trypanosomes in vitpo. 
Oxygen consumption of trypanosomes was measured before and after drug 
addition. 
Table 3.15: OXygen consumption by ·tryPlI!nosomes·in vitpo in the 
presence of daunorubicin analogues. 
Concentration 02 consumption % Oxygen Loss of Drug (nullo!) (nmol/min/l06 Consump- motility 
cells tion (1) (2) -
Daunorubicin none 11.5 100 ++ 
0.01 10.9 94.4 
0.1 4.2 36.7 -
N-Acetyldaunorubicin none 12.9 100 ++ 
0.01 13.7 106.5 
0.1 14.6 112.9 ++ 
5-Iminodaunorubicin none 12.9 100 ++ 
0.01 12.4 96.5 
I 
0.1 11.5 89.3 +-
(1) Expressed as percentage of oxygen consumption in the absence of drug 
(2) ++ no loss of motility 
+- loss of motility, trypanosomes still motile 
total loss of motility. 
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Figure 3.31: Effect of daunorubicin derivatives on oxygen consumption 
of trypanosomal homogenate 
















































conjugate (fraction II) 
Figure 3.32: Effect of daunorubicin derivatives on oxygen consumption 
of liver microsomes 
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Increased oxygen consumption was apparent in the presence of 
N-acetyldaunorubicin and no loss of motility was observed on microscopic 
examination. In contrast to this, trypanosomes in the presence of 
0.1 mM 5-iminodaunorubicin showed partial loss of motility and in the 
presence of 0.1 roM dauno,rubicin showed complete loss of motility. The 
motility of trypanosomes can be correlated with rates of oxygen consumption 
and glycolysis (Williamson et al., 1975). With the exception of 
N-acetyldaunorubicin, which is only weakly trypanocidal (section 3.2), 
any stimulation of oxygen consumption due to the formation of oxygen 
radicals appeared to be masked by the decrease in motility. 
The effect of daunorubicin analogues on the oxygen consumption of 
liver microsomes and trypanosomal homogenate was also measured and these 
results are presented in Figures 3.31 and 3.32. In both experiments 
the greatest increase in oxygen consumption was seen in the presence of 
daunorubicin. Precipitation of trypanosomal homogenate occurred at 
0.1 roM daunorubicin, which may account for the inhibiting effect seen 
at this concentration. Daunorubicln-BSA conjugate linked via glutar-
aldehyde (fraction II) also caused a slight increase in oxygen consumption 
in trypanosomal homogenate. This may be caused by the presence of 
free daunorubicin released by enzymic hydrolysis of the drug-glutaraldehyde 
linkage. 5-Iminodaunorubicin slightly quenches oxygen consumption in 
liver microsomes and trypanosomal homogenate. The relative inactivity 
of 5-iminodaunorubicin catalysing production of oxygen radicals has 
been noted previosuly in heart tissue. Davies et al. (1983) found 
that daunorubicin stimulated production of superoxide, hydrogen peroxide 
and hydroxyl radicals in rotenone inhibited beef-heart submitochondrial 
particles. Stimulation by 5-iminodaunorubicin under the same conditions 
was less than 7.5% of that produced by doxorubicin. 
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The anthracycline drugs used in this study may be divided into two 
groups on the basis of their ability to stimulate lipid peroxidation 
and oxygen consumption in liver microsomes, which was used as a model 
system. Daunorubicin and N-acetyldaunorubicin stimulated lipid 
peroxidation and oxygen consumption in liver microsomes in vitro and 
lipid peroxidation in liver microsomes from drug treated mice. In 
contrast, 5-iminodaunorubicin inhibited lipid peroxidation and oxygen 
consumption under identical conditions. In trypanosomes, however, 
this apparent difference between the drugs was not as marked. Lipid 
peroxidation of trypanosomal microsomes only occurred in the presence of 
added ferric ion and under such conditions no significant differences 
in lipid peroxidation induced by these drugs could be found. All of 
the drugs caused an increase in oxygen consumption of trypanosomal 
homogenate, although the increase caused by daunorubicin and N-acetyl-
daunorubicin was much greater than that caused by 5-iminodaunorubicin. 
All three drugs increased lipid peroxidation in trypanosomes isolated 
from drug treated mice. N-Acetyldaunorubicin produced a much greater 
increase in lipid peroxidation than either daunorubicin or 5-imino-
daunorubicin. 
3.6 General Discussion 
At the beginning of this study, daunorubicin was known to possess 
trypanocidal properties, but these could not be translated into in vivo 
activity. In this study a series of daunorubicin analogues and 
derivatives were synthesised and tested for trypanocidal activity, but 
only glutaraldehyde linked daunorubicin conjugates were found to be 
active in vivo, when tested against Trypanosoma rhodesiense in mice. 
The next part of this study concentrated on the factors which 
affected the activity of these conjugates. Variation in the macromolecule 
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used produced minor changes in conjugate activity. Neutral, positive 
and negatively charged macromolecules possessed approximately equal 
activity, which might reflect a lack of specificity of macromolecule 
uptake by trypanosomes. Trypanosomes are known to avidly take up 
proteins by endocytosis. 
In contrast, the drug-macromolecule linkage had a major effect on 
the activity of the conjugates. Apart from glutaraldehyde, all other 
linking agents produced conjugates which were inactive in vivo. 
Inv€5dgation of drug release showed that glutaraldehyde linked 
daunorubicin-bovineserumalbumin conjugate released between 5 and 12% 
of drug when incubated in pH 7.4 buffer. The amount released depended 
on the concentration of drug originally linked to the carrier. However, 
in murine plasma and trypanosomal homogenate approximately 35% of drug 
was released. Conjugate from which all weakly bound drug had been 
removed (fraction II) released a further 12% in murine plasma and 
trypanosomal homogenate. A fraction of the drug made available to 
trypanosomes in vivo by glutaraldehyde linked conjugate is probably 
enzymically released. It would appear that glutaraldehyde linked 
conjugate contains at least two bond types. A labile bond which is 
cleaved in pH 7.4 buffer and a bond which is only cleaved in biological 
systems. Drug which cannot be cleaved by presumably enzymic hydrolysis 
may represent a third bond type, or may not be available for enzymic 
cleavage owing to steric hindrance by the bulky carrier molecule. 
The time interval over which drug is released may be an important 
factor in the activity of daunorubicin conjugates in vivo. 
Glutaraldehyde linked conjugates released drug over a two-hour period. 
In contrast, hydrazone and oxime linked conjugates released drug very 
rapidly in pH 7.4 buffer, hence drug will be released before entry 
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into trypanosomes. The rate of drug release was too rapid to measure 
in murine plasma and trypanosomal homogenate. Succinyl linked conjugate 
released about 3% of bound drug during the first thirty minutes of 
incubation, with none being released thereafter. The period over which 
drug is released is therefore an important difference between glutar-
aldehyde linked conjugate and the inactive conjugates tested. 
Historically, daunorubicin has been thought to act by interaction 
with nuclear DNA (Hepry, 1975), but in recent years, other cytotoxic 
'mechanisms of action have been proposed. These have included generation 
of reactive oxygen species (Bachur et al., 1979), and interaction with 
the cell surface membrane (Tokes et a1., 1982). Glutaraldehyde linked 
daunorubicin conjugate could be postulated to act by anyone, or more, 
of these mechanisms, either by prior release of daunorubicin close to 
the target site, or as a drug in its own right. Arnon and Sela (1982) 
showed that a daunorubicin-dextran conjugate was able to reach the 
nucleus of tumour cells while Lewis (1974) has reported that antibodies 
which are commonly used as carrier molecules, can be found in the 
nuclei of tumour cells. In the present study, glutaraldehyde linked 
daunorubicin-BSA conjugate showed no evidence of interaction with DNA, 
as judged by spectrophotometric titration and pH shift (Figures 3.24 
and 3.25). It also does not markedly stimulate oxygen consumption in 
trypanosoma1 homogenate (Figure 3.31) and also inhibits, rather than 
stimulates, lipid peroxidation in trypanosomal homogenate (Table 3.12), 
and so is unlikely to act by generation of reactive oxygen species. 
Glutaraldehyde linked conjugate may be acting on the trypanosome surface 
membrane and this possibility needs investigating. However, the 
structurally similar succiny1 linked conjugate was inactive in vivo. 
We can thus eliminate the hypothesis that daunorubicin conjugates are 
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active prior to drug release. In support of this conclusion this study 
has shown that activity of daunorubicin-BSA conjugates is related to 
the lability of the linkage. This is supported by a similar study using 
daunorubicin-BSA conjugate against tumour cells. 
Brown et al. (1982) showed that trypanosomes in mice infected 
with 25 mg/kg daunorubicin were exposed to concentrations 500-fold 
greater than that required for in vitro activity, over a period of 
six hours. There is evidence that trypanosomes actively excrete 
daunorubicin (Brown et al., 1982a), and the bloodstream form may be 
able to eliminate drug more effectively than the in vitro form. Since 
daunorubicin remains in the nucleus of the trypanosome bloodstream 
form for a short period, it may delay cell division rather than totally 
inhibit cell division as occurs in the in vitro form (Brown et al., 1982a) 
A conjugate which releases drug over a prolonged period would be 
expected to provide a continuous intracellular drug concentration, 
thus inhibiting cell division. Although the breakdown study in 
trypanosomal homogenate only showed drug release over a two-hour period, 
this might be considerably longer in vivo since metabolic breakdown 
of the carrier proteins might expose more of the bound drug to 
hydrolytic enzymes. 
Investigation of the mechanism of trypanocidal action of 
daunorubicin was concentrated on intercalation and free radical damage 
as indicated by lipid peroxidation. The interaction of several 
anthracyclines with DNA was studied using a series of tests which 
measured changes in the properties of the drug and of DNA. Of those 
tests. a study of the thermal denaturation of DNA in the presence of 
drug is the most suitable for comparison with trypanocidal properties 
since it measured a quantitative change in DNA and is applicable to 
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all drugs. A comparison of change in thermal denaturation temperature 
with drug activity against T. rhodesiense in vitro is shown in Table 3.16. 
From this table it is clear that only daunorubicin and nogalamycin 
are active in vitro. 5-Iminodaunorubicin, which also binds to DNA, 
although not as avidly as daunorubicin is, however, inactive. The 
physical characteristics of a series of daunorubicin derivatives are 
compared with their activity against T. rhodesiense in Table 3.17. 
The three drugs which exhibit high in vitro activity also bind strongly 
to DNA as shown by their high affinity constants and 6Tm valu~s. In 
vitro activity of these drugs is not directly related to their affinity 
for DNA, since doxorubicin and 3,4-diepidaunorubicin have higher 
7 affinity constants than daunorubicin, yet they are 10 times less 
active in inhibiting trypanosome infectivity in vitro. The large 
differences in potency between these closely related drugs may be 
considered to be due to pharmacokinetic differences between them, or to 
two or more different mechanisms of action. 
Partition coefficient is an important physicochemical parameter 
governing the rate of uptake of drugs by cells. Drugs with relatively 
high partition coefficients are accumulated more rapidly than less 
lipophilic drugs. This may explain why daunorubicin, which is three 
times as lipophilic as doxorubicin, is more active in vitro, despite 
having a lower affinity for DNA. Doxorubicin also has a slightly 
greater inhibiting effect on DNA and RNA synthesis in cell-free systems 
than daunorubicin (Zunino et al., 1975), but is less active than 
daunorubicin in tumour cells in vitro. the difference being due to 
greater cellular uptake by daunorubicin (Meriwether and Bachur, 1972). 
Enhanced uptake of daunorubicin compared with doxorubicin has been 
observed in tumour cells by Kessel (1974). 4-Demethoxydaunorubicin 
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Table 3.16: Comparison of change 1n thermal denaturation temperature 
( 11 Tm) with in vitro inhibition of infectivity and 
motility in T. rhodesiense 
, 




in thermal infectivity of motility 
dena tura tion 
temperature 
( 11 Tm) (OC) Temporary Permanent 
Daunorubicin 14.8 11 10 4 
Nogalamycin 14.2 > 9 6 4 




5 < 3 < 3 
daunorubicin 
7-0-Methyl- 1. 75 ! , 8 < 3 4 
nogarol I 
N,N-Dibenzyl- 0.6 < 3 < 3 < 3 
daunorubicin 
-1 
(1) Values are the maximum titres (10&,0 M ) producing the effect; 





Table 3.17: Comparison of activity against T. rhodesiense with physical characteristics for a series of 
daunorubicin derivatives 
Drug Inhibition of 1 Inhibition
' 
In vivo 4 Affinity2 /). Tm Partition 3 K 5 P a 
infectivity of motility pro longation constants ( 0 C) coeff-
Temporary Permanent of infection (M-
1xl0-5) icient 
Daunorubicin 11 10 4 2.9 13.3 14.8 17.8 8.46 
Doxorubucin 10 4 8 1.5 18.8 16.25 6.3 8.34 
3, 4-Diepi- 10 10 5 1.0 9.7 12.7 - -
daunorubl.c1.n 
4-Deoxy- 6 3 5 2.0 - - - -
daunorubicin 
4-Deoxy- 6 3 5 0.5 5.3 8.7 15.0 -
, doxorubicin 




4 3 3 2.0 - 9.1 - -i daunorubicin 
j 
----~~-- ~- ------ - ~- ---_ .. -
(1) Values are maximum titres (10g,0 M- 1) producing the effect; drugs with titres <3 are considered inactive 
(2) Plumbridge and Brown, 1979 
(3) Cassazza, 1979 n-butanol/tris buffer pH 7.4 
(ld Administered as a ~lutaraldehyde linked BSA conjugate (15 mg'kg) 
(5) Zunino et al., 1979 
Data unknown 
gives an inhibition of nucleic acid synthesis 1n tumour cells equivalent 
to that of daunorubicin (Zunino ct al., 1976) and is more potent than 
daunorubicin against tumour cells in vitro and in vivo (Cassazza, 1979). 
Cellular uptake was fifteen times greater than daunorubicin in L1210 
cells in vitro, hence high uptake and consequent activity might be 
expected in trypanosomes. However, 4-demethoxydaunorubicin was only 
marginally active in vitro, hence differences in lipophilicity cannot 
account for the relative activities of these drugs. 
The pKa is also an important factor affecting cellular uptake of 
drugs, as it is generally considered that only the neutral form will 
passively diffuse into the cell. From the pKa data available in 
Table 3.17, it can be calculated from the Henderson-Hasselbach equation 
that there will be approximately 8, 10 and 25% of daunorubicin, 
doxorubicin and 4-demethoxydaunorubicin respectively in the neutral 
form at pH 7.4. Other drugs in Table 3.17 will have similar pKa 
values owing to their similar structure. Since 4-demethoxydaunorubicin 
is the most unionised drug at physiological pH, the relative lower 
pKa should favour uptake of this drug. However, since 4-demethoxy-
daunorubicin is only marginally active, pKa alone is not sufficient 
to explain differences between drugs. 
An alternative explanation of these phenomena is that the 
anthracycline antibiotics are operating by two or more mechanisms of 
action and that changes in molecular character modify involvement with 
one particular mechanism of action, but do not affect (or possibly 
enhance) involvement with either mechanisms of action. The high activity 
shown by daunorubicin in vitro may therefore be due to a synergistic 
interaction of DNA binding with some other mechanism of action not 
shared by 4-demethoxydaunorubicin and other marginally active DNA 
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binding drugs. Daunorubicin and doxorubicin produce many effects on 
living cells which may be involved in cytotoxicity. These have included 
effects on the cell membrane such as transport of small molecules 
(Dasdia et a1., 1979), fluidity (Murphree et al., 1981), covalent 
binding to phospholipids and proteins (Schwartz et a1., 1978) and 
lipid peroxidation. Other effects which have been noted include· 
inhibition of mitrochondrial activity (Andreini and Beretta, 1977). 
Some clues to discovering which of the many possible mechanisms 
of action may be important for a trypanocidal effect may be found 
from ultrastructural studies. 
Many of the actions of the anthracyclines which are not directed 
specifically to DNA replication and synthesis may be due to lipid 
peroxidation. Generation of reactive oxygen species and resultant 
lipid peroxidation was considered a potentially important mechanism 
of cytotoxicity owing to the vulnerability of trypanosomes to these 
species (Meshnick et al., 1978). Ultrastructural studies of 
trypanosomes treated with haem, a compound known to mediate its 
cytotoxicity by production of hydroxyl radicals, revealed swelling of 
the endoplasmic reticulum and nuclear envelope (Meshnick et al., 1977). 
Trypanosomes treated with daunorubicin did not show these features, 
although there were some indications of membrane damage, most notably 
the formation of cytoplasmic clefts and autophagic vacuoles (Williamson) 
et al., 1972). Delain et al. (1982) also noted that daunorubicin 
caused rearrangement of kinetoplast DNA. However, it is unlikely that 
anthracycline induced lipid peroxidation is trypanocidal since in 
this study, N-acetyldaunorubicin, which caused the greatest amount of 
lipid peroxidation in trypanosomes in vivo was active, but 
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S-iminodaunorubicin, which caused little lipid peroxidation, was active 
when given as a glutaraldehyde conjugate (see Table 3.10). However, 
reactive oxygen species do not necessarily produce lipid peroxidation 
and their attack on cell components other than lipid membranes may be 
important. Other effects of free radicals, such as depletion of NADPH 
and glutathione, have not been investigated, although Arrick et ale 
(1981) have shown that inhibiters of glutathione biosynthesis are 
trypanocidal. 
Bachur et ale (1978) have postulated that anthracycline semiquinone-
free radicals may intercalate into DNA and covalently bind to it, or 
generate reactive oxygen radicals in close proximity to DNA and these 
may then react with the DNA. Covalent binding of daunorubicin and 
doxorubicin to DNA has been demonstrated by Sinha and Chignell (1979). 
This hypothesis might explain the high in vitro activity of daunorubicin 
compared with 5-iminodaunorubicin. Since daunorubicin stimulates 
oxygen consumption in trypanosomal homogenate and is known to form 
semiquinone radicals, these might covalently bind to trypanosomal DNA 
when treated in vitro. If these drug-treated parasites are injected 
into mice, daunorubicin cannot dissociate from the DNA and so permanently 
inhibit multiplication of the parasite. 5-Iminodaunorubicin does not 
readily form semiquinone radicals, and also inhibits oxygen consumption 
in trypanosomal homogenate and is therefore unlikely to react covalently 
with DNA. If trypanosomes treated with 5-iminodaunorubicin are 
injected into mice, drug will disassociate from DNA and multiplication 
will not be inhibited. These differences will not be important if the 
drugs are administered as a glutaraldehyde conjugate since drug will 
be available to the trypanosome over a long period of time. 
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In conclusion, the mechanism of action of daunorubicin was 
investigated and a relationship between trypanocidal activity and DNA 
binding ability was revealed. Some DNA binding drugs were not active 
in vitro, suggesting that other mechanisms of action might also be 
important. Generation of free radical species by the anthracyclines 
as suggested by monitoring the free radical process lipid peroxidation 
was investigated, but the results suggest that lipid peroxidation 
produced by anthracycline generated free radicals is not an important 
mechanism of cytotoxicity. 
This study has also shown that the potent in vitro trypanocidal 
activity of daunorubicin may be reproduced in vivo by formation of a 
macromolecular conjugate. Some of the factors which might affect the 
activity of these conjugates have been investigated and development of 
improved conjugate linkages has been attempted. 
The use of macromolecular conjugates may, in future, be used for 
other drugs and in the treatment of other diseases. Targeting of drugs 
via conjugate formation may enhance the activity of weakly active 
drugs, and may overcome problems of drug resistance, such as the 
widespread resistance of malaria parasites to chloroquine. Some work 
in this direction has recently been published by Trouet et ale (1982) 
who showed that formation of a labile conjugate of primaquine greatly 
enhanced its activity against PZasmodium berghei. 
Da~norubicin is far from being an ideal drug for the treatment of 
trypanosomiasis on account of its high cost and toxicity. However, 
mitoxantrone and similar synthetic drugs based on the anthraquinone 
structure may provide an inexpensive alternative as mitoxantrone has 
been shown to possess activity against experimental tumours (Cheng et 
al., 1979~, and is less toxic than daunorubicin (Zbinden and Beilstein, 
1982). 
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Labile macromolecular conjugates of the type described in this 
thesis are important in overcoming problems of drug delivery and low 
therapeutic index. As they are applicable to so many drugs, it is 
expected that their use in antiprotozoal chemotherapy will become 
far more common than it is today. 
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Preparation of buffers and physiological media 
(a) Phosphate buffered saline (P.B.S.) pH 7.4 contains: 
Na2HP04 
- 66 roM (9.37g/L) 
KH2PC4 - 8.7 mM (1.18g/L) 
NaCl - 150 mM (8.766g/L= 
(b) Tris buffer A pH 7.4 contains: 
NaCl - 50 roM (2.92g/L) 
NH2C(CH20H)3 - (0.969g/L) 
neutralised to pH 7.4 with hydrochloric acid 
(c) Tris buffer B pH 7.4 contains: 
EDTA 2 mM (0.584g/L) 
neutralised to pH 7.4 with hydrochloric acid 
(d) Citrate saline contains: 
NaCl - 145 mM (8.5g/L) 
Sodium Citrate - 58 mM (15g/L) 
The solution was filtered and then sterilised in 
an autoclave. 
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(e) Kreb's phosphate saline contains: 
0.9% NaCl - 1L 
1.15% KCl - 40 ml 
3.84% MgS04 .7H20 - 10 ml 
* 0.1M phosphate buffer - 300 m1 
* Buffer contains: 
- 100 mM (14.2g/L) 
- 20 ml 
(f) Kreb's glucose contains: 
Glucose - 111 mM (20g/L) in Kreb's phosphate saline solution. 
(g) NADPH generating solution contains: 
NADP (1.62 mg/m1) 
G1ucose-6-phosphate (2.61 mg/m1) 
Glucose-6-phosphate dehydrogenase - 1.5 units/ml 
MgC1 2 (1M) -.10 ~l 
in 1 ml of 0.1M phosphate buffer pH 7.4* 
* 0.1M phosphate buffer contains 
0.2M disodium hydrogen phosphate - 40.5 m1 
0.2M sodium dihydrogenphosphate - 9.5 ml 
made up to 100 ml with water. 
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